"","...1","Disease","Enrichment.biomarker","Biomarker.relationship","Biomarker.logical.conditions","Marker.type","Drug","Targets","Study.Phase..comparator.","Clinical.State.and.treatment.setting","Primary.End.Point","clinicaltrials.gov.reference","Raw.Text","annotator","STATUS","validator","URL","drug_drugbank_standard","drug_pubchem","biomarker_ensembl_standard","diseases_EFO_MONDO_standard","biomarker_term","QC"
"1",1,"UNRESPECTABLE MIDDLE-ADVANCED HEPATOCELLULAR CARCINOMA","absent","NA","NA","NA","ANLOTINIB","UNK","II","Advanced, First Line","Time To Progression(TTP)","NCT04157140","Uses TACE+RFA ( radiofrequency ablation (RFA) and transcatheter arterial chemoembolization(TACE)), defines cancer as middle-advanced HCC","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT04157140","DB11885","57380530","ENSG00000104313","EFO_0009260","ABSENT NA NA","no biomarker"
"2",2,"RESECTABLE ADVANCED HEPATOCELLULAR CARCINOMA","absent","NA","NA","NA","SORAFENIB","UNK","II","Advanced, First Line","Recurrence-free survival","NCT04143191","Active comparator uses sorafenib. Testing Sorafenib plus TACE, cannot have metastasis, needs to have received received curative hepatic resection","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT04143191","DB00398","406563","ENSG00000104313","EFO_0009260","ABSENT NA NA","no biomarker"
"3",3,"LOCALLY ADVANCED UNRESECTABLE HEPATOCELLULAR CARCINOMA","absent","NA","NA","NA","DURVALUMAB, YTTRIUM-90 MICROSPHERES","UNK, UNK","I, II","Advanced, First Line","TTP","NCT04124991","Transarterial radioembolization (TARE) with yttrium-90 microspheres will be employed in combination with an intravenous (IV) dose of 1500 mg durvalumab every 4 weeks (Q4W) until PD","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT04124991","DB11714,NA","NA, NA","ENSG00000104313","EFO_0009260","ABSENT NA NA","no biomarker"
"4",4,"ADVANCED STAGE HEPATOCELLULAR CARCINOMA","HBsAg","Positive","NA","Protein Expression","DURVALUMAB, SORAFENIB, LENVATINIB, REGORAFENIB, CABOZANTINIB","UNK, UNK, UNK, UNK, UNK","II","Advanced, Second Line","Time to decline to ≥ 2 log10 IU/mL of serum HBsAg","NCT03899428","HCC cases related to chronic HBV expression HBV ABsAg antigen. Needs to have been treated with either entecavir or tenofovir or TAF before initiation of anti-PDL1 or TKI, cannot receive radiation prior","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03899428","DB11714,DB00398,DB09078,DB08896,DB08875","NA, 406563, 11237762, 11167602, 25102846","NA","EFO_0009260","HBSAG PROTEIN EXPRESSION POSITIVE","failed biomarker"
"5",5,"RECURRENT OR METASTATIC HEPATOCELLULAR CARCINOMA","Absent","NA","NA","NA","CYCLOPHOSPHAMIDE, CYTOKINE-BASED BIOLOGIC AGENT IRX-2, NIVOLUMAB","UNK, UNK, UNK","I","Advanced, Second Line","Recommended phase II dose","NCT03655002","NA","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03655002","DB00531,NA,DB09035","2907, NA, NA","ENSG00000104313","EFO_0000702","ABSENT NA NA","pass"
"6",6,"ADANCED HEPATOCELLULAR CARCINOMA","Globo-H, SSEA-3, GALNT14","Positive, Positive, Negative","OR, AND","Protein Expression, Protein Expression, polymorphism","ADAGLOXAD SIMOLENIN","UNK","II","Advanced, First Line","time-to-ITTVP","NCT03608878","Patients should be in BCLC clinical stage B (multinodular asymptomatic tumors without extra-hepatic spread or portal vein invasion) with or without unilateral secondary or tertiary branches of portal vein invasion. Uses TACE. GALNT-14 ""non TT"" found polymorphism at https://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.e15657","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT03608878","NA","NA","NA, NA, ENSG00000158089","EFO_0000707","GLOBO-H PROTEIN EXPRESSION POSITIVE OR SSEA-3 PROTEIN EXPRESSION POSITIVE AND GALNT14 POLYMORPHISM NEGATIVE","failed drug,failed biomarker"
"7",7,"ADVANCED HEPATOCELLULAR CARCINOMA","Absent","NA","NA","NA","ANLOTINIB HYDROCHLORIDE","VEGFR, FGFR, PDGFR, CKIT","II","Advanced, First Line","Disease free survival","NCT04213118","Procedure: TACE, requires hepatectomy","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT04213118","NA","57380530","ENSG00000104313","EFO_0009260","ABSENT NA NA","pass"
"8",8,"HEPATOCELLULAR CARCINOMA (IIIB-IV)","AFP","Positive","NA","Protein Expression","COLCHICINE","UNK","II","Advanced, Second Line","survival","NCT04264260","Primary hepatic malignant tumors unable to receive curative treatment indicate that the malignancy can not be completely eliminated by operative resection, liver transplantation or local abrasion therapy. Patient also needs to fit at least one of the following criteria: (1) evidence of distant metastasis or large vessels (intrahepatic first branch portal vein, portal main trunk, major hepatic vein or inferior vena cava) invasion, (2) unable to be controlled by transcatheter arterial chemoembolization including appearance of new rather than incompletely treated nodules within 3 months of chemoembolization, or chemoembolization fails","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT04264260","DB01394","6167","ENSG00000081051","EFO_0000707","AFP PROTEIN EXPRESSION POSITIVE","pass"
"9",9,"HEPATOCELLULAR CARCINOMA","absent","NA","NA","NA","APATINIB MESYLATE, SHR-1210","UNK, PD1","II","First line","Recurrence-free survival(RFS)","NCT03839550","active comparator: Twice standard HAI treatment, the first treatment was performed 4-8 weeks after radical hepatic resection, and the second treatment was given 4-8 weeks after the first treatment, patients need to have surgical resection","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT03839550","NA,NA","45139106, NA","ENSG00000104313","EFO_0000182","ABSENT NA NA","no biomarker"
"10",10,"ADVANCED HEPATOCELLULAR CARCINOMA","absent","NA","NA","NA","PEMBROLIZUMAB, NIVOLUMAB","UNK, UNK","II","Advanced, Second Line","Adverse events, Response","NCT03939975","therapy in combination with thermal ablation. Patients need to have had advanced stage of disease that is refractory to or is with unacceptable toxicity of sorafenib","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT03939975","DB09037,DB09035","NA, NA","ENSG00000104313","EFO_0009260","ABSENT NA NA","no biomarker"
"11",11,"RESECTABLE HEPATOCELLULAR CARCINOMA","absent","NA","NA","NA","TORIPALIMAB","UNK","I, II","First Line","Pathological response rate","NCT03867370","Trials include other cancer ( Intrahepatic Cholangiocarcinoma. Patients cannot have Patients known to have fibrous layer HCC, sarcomatoid HCC. Must be eligible for resection","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT03867370","DB15043","NA","ENSG00000104313","EFO_0000707","ABSENT NA NA","no biomarker"
"12",12,"HEPATOBILIARY NEOPLASM (IV)","absent","NA","NA","NA","AXITINIB, TORIPALIMAB","VEGFR, PD1","II","Advanced, Second Line","objective response rate (ORR), Progression-free Survival (PFS)","NCT04010071","Only can start after failure on another treatment: Definition of treatment failure: Disease progression during treatment or relapse after treatment, such as after at least once radical or palliative resection surgery, revenue recurrence or progression after intervention therapy or radiotherapy. Intervention therapy or oxaliplatin treatment must be more than 1 cycle, and molecular targeted therapy must more than ≥14 days.","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT04010071","DB06626,DB15043","6450551, NA","ENSG00000104313","EFO_0008550","ABSENT NA NA","no biomarker"
"13",13,"INTERMEDIATE STAGE HEPATOCELLULAR CARCINOMA","absent","NA","NA","NA","NIVOLUMAB","UNK","II, III","First Line","Overall Survival - phase III primary outcome, Time to TACE Progression (TTTP) - phase II primary outcome","NCT04268888","using TACE procedure, Active comparator is doxorubicin hydrochloride. Cannot be a candidate for surgical resection or liver transplantation, cannot have metastasis outside liver","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT04268888","DB09035","NA","ENSG00000104313","EFO_0000707","ABSENT NA NA","no biomarker"
"14",14,"HEPATOCELLULAR CARCINOMA","absent","NA","NA","NA","PEMBROLIZUMAB","UNK","I","First Line","Have technically resectable HCC, with complete extirpation of HCC at end of surgery by resection +/- intra-operative radiofrequency ablation (RFA) at time of enrolmen","NCT04224480","NA","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT04224480","DB09037","NA","ENSG00000104313","EFO_0000182","ABSENT NA NA","no biomarker"
"15",15,"UNRESECTABLE LOCALLY ADVANCED OR METASTATIC HEPATOCELLULAR CARCINOMA","absent","NA","NA","NA","SITRAVATINIB, TISLELIZUMAB","UNK, UNK","I, II","Advanced, Second Line","Phase 1: Number of participants with adverse events (AEs) and serious adverse events (SAEs) per NCI-CTCAE version 5.0","NCT03941873","Cohorts, A: Anti-PD-1/PD-L1 antibody naive HCC, B: Anti-PD-1/PD-L1 antibody refractory/resistant HCC, Sitravatinib used as a monotherapy as well. Must have Failed current standard-of-care treatment, or standard-of-care treatment is considered not appropriate at present","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT03941873","DB15036,DB14922","25212148, NA","ENSG00000104313","EFO_0009260","ABSENT NA NA","no biomarker"
"16",16,"RESECTABLE HEPATOCELLULAR CARCINOMA","absent","NA","NA","NA","CEMIPLIMAB","UNK","II","First Line, Second Line","Significant tumor necrosis (STN) at time of surgery is the primary endpoint for the HCC cohort","NCT03916627","Patient must be determined to be a surgical candidate for resection of their tumor. Others cancers in trial, Separate HCC cohort","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT03916627","DB14707","NA","ENSG00000104313","EFO_0000707","ABSENT NA NA","no biomarker"
"17",17,"HEPATOBILIARY TUMORS","IDH1-R132","Positive","NA","mutation","FT-2102, NIVOLUMAB","UNK, UNK","I, II","Advanced, Second Line","Number of participants with a Dose Limiting Toxicity (DLT) [Phase 1], Doses recommended for future studies [Phase 1]","NCT03684811","Multiple cancers studied in different cohorts. Hepatobiliary cancer that is relapsed/refractory or intolerant to approved standard-of-care therapy (included: hepatocellular carcinoma, bile duct carcinoma, intrahepatic cholangiocarcinoma or other hepatobiliary carcinomas).","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03684811","NA,DB09035","118955396, NA","NA","EFO_0008550","IDH1-R132 MUTATION POSITIVE","failed biomarker"
"18",18,"HEPATOBLASTOMA OR HEPATOCELLULAR CARCINOMA","INI1/SMARCB1","Positive","NA","Protein Expression","CARBOPLATIN, CISPLATIN, DOXORUBICIN, ETOPOSIDE, FLUOROURACIL, GEMCITABINE, IRINOTECAN, OXALIPLATIN, SORAFENIB, VINCRISTINE SULFATE","UNK, UNK, UNK, UNK, UNK, UNK, UNK, UNK, UNK, UNK","II, III","First Line","Event-free survival (EFS), Percentage of Group B2 participants with resectable tumors, Response rate for Group F patients","NCT03533582","Active comparator: Patients undergo observation. Found infromation of SMARCB1/INI1: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5406539/. Trial has multiple arms with some patients getting surgery, no surgery, and also just observation. Some cohorts are seperated by WDF status. Treating Children and young adults","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT03533582","DB00958,DB00515,DB00997,DB00773,DB00544,DB00441,DB00762,DB00526,DB00398,NA","56840877, 2767, 443939, 36462, 3385, 60750, 60838, 5310940, 406563, 5388992","NA","EFO_0000707","INI1/SMARCB1 PROTEIN EXPRESSION POSITIVE","failed biomarker"
"19",19,"HEPATOCELLULAR CARCINOMA","AFP","Positive/Negative","NA","Protein Expression","PRAVASTATIN","UNK","II","Second Line","Time to Recurrence","NCT03219372","Must have AFP < 400 ng/mL","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT03219372","DB00175","16759173","ENSG00000081051","EFO_0000182","AFP PROTEIN EXPRESSION POSITIVE/NEGATIVE","pass"
"20",20,"HEPATOCELLULAR CARCINOMA","VEGF, AFP","Positive, Positive","AND","Protein Expression, Protein Expression","APATINIB","VEGFR","II","First line","overall survival","NCT03511703","Second arm is standard treatment with TACE: Intra-arterial infusion chemotherapy for tumors, commonly used chemotherapy drugs include anthracyclines, platinum, etc.; chemotherapeutic drugs and embolic agents are mixed together and injected through the blood supply artery of the tumor. The most commonly used embolic agent for TACE treatment is a lipiodol emulsion.","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT03511703","DB14765","45139106","ENSG00000112715, ENSG00000081051","EFO_0000182","VEGF PROTEIN EXPRESSION POSITIVE AND AFP PROTEIN EXPRESSION POSITIVE","pass"
"21",21,"UNRESECTABLE INTRAHEPATIC CHOLANGIOCARCINOMA","absent","NA","NA","NA","IRINOTECAN, OXALIPLATIN, FLUOROURACIL, LEUCOVORIN","UNK, UNK, UNK, UNK","III","Advanced, First Line","Overall survival","NCT03771846","Experimental arm: Hepatic artery infusion chemotherapy, Active comparator: Participants received systemic chemotherapy of gemcitabine and oxaliplatin, cannot be amendable to surgical resection ,local ablative therapy and any other cured treatment","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03771846","DB00762,DB00526,DB00544,DB00650","60838, 5310940, 3385, 135403647","ENSG00000104313","EFO_0000313","ABSENT NA NA","no biomarker"
"22",22,"LOCALLY ADVANCED CHOLANGIOCARCINOMA NON-RESECTABLE","absent","NA","NA","NA","GEMCITABINE, OXALIPLATIN","UNK, UNK","II","Advanced, Second Line","objective response rate","NCT03364530","Histologically-proven intrahepatic cholangiocarcinoma previously treated by first-line systemic therapy","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03364530","DB00441,DB00526","60750, 5310940","ENSG00000104313","EFO_0009260","ABSENT NA NA","no biomarker"
"23",23,"UNRESECTABLE CHOLANGIOCARCINOMA","absent","NA","NA","NA","ABC294640, HYDROXYCHLOROQUINE SULFATE","SK2, autophagy","II","First Line, Second Line","Part1 - Determine Response Rate, Part 2 - Determine the Durable Disease Control Rate","NCT03377179","Patients with histologically confirmed intrahepatic, perihilar or extra-hepatic CCA.","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03377179","NA,NA","15604015, 12947","ENSG00000104313","EFO_0000313","ABSENT NA NA","no biomarker"
"24",24,"HIGH RISK INTRAHEPATIC CHOLANGIOCARCINOMA (IB, II, III, IIIA, IIIB)","absent","NA","NA","NA","GEMCITABINE, CISPLATIN, NAB-PACLITAXEL","UNK, UNK, UNK","II","First Line","Completion of all preoperative and operative therapy, Incidence of adverse events","NCT03579771","high-risk but technically resectable intrahepatic cholangiocarcinoma and is completed with surgical resection, must receive surgical resection","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03579771","DB00441,DB00515,NA","60750, 2767, 36314","ENSG00000104313","EFO_0000313","ABSENT NA NA","no biomarker"
"25",25,"ADVANCED OR METASTATIC HEPATOCELLULAR CARCINOMA","absent","NA","NA","NA","REGORAFENIB, AVELUMAB","UNK, UNK","II","Advanced, First Line, Second Line","Recommended phase II dose (RP2D) Assessment of the antitumor activity of regorafenib","NCT03475953","NA","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03475953","DB08896,DB11945","11167602, NA","ENSG00000104313","EFO_0009260","ABSENT NA NA","no biomarker"
"26",26,"ADVANCED OR METASTATIC BILLARY TRACT CANCER","absent","NA","NA","NA","REGORAFENIB, AVELUMAB","UNK, UNK","I, II","Advanced, First Line, Second Line","Assessment of the antitumor activity of regorafenib","NCT03475953","NA","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03475953","DB08896,DB11945","11167602, NA","ENSG00000104313","MONDO_0002516","ABSENT NA NA","no biomarker"
"27",27,"BILLARY TRACT CANCER","absent","NA","NA","NA","IRINOTECAN LIPOSOME, 5-FLUOROURACIL, LEUCOVORIN","UNK, UNK, UNK","II","Advanced, First Line","Progression-free survival [PFS]","NCT03044587","hepatocellular carcinoma, and other cancers, are listed in beginning of trial but not in inclusion criteria. Intra/extrahepatic billary tract cancers are both accepted. Active comparator: Arm Cisplatin + Gemcitabine (Arm B, standard of care)","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03044587","NA,DB00544,DB00650","NA, 3385, 135403647","ENSG00000104313","EFO_0000311","ABSENT NA NA","failed drug,no biomarker"
"28",28,"UNRESECTABLE INTRAHEPATIC CHOLANGIOCARCINOMA","absent","NA","NA","NA","MELPHALAN, CISPLATIN, GEMCITABINE","UNK, UNK","II, III","First Line, Second Line","Overall Survival","NCT03086993","The active comparator is just treatment with Cisplatin and Gemcitabine. Drugs delivered using Percutaneous Hepatic Perfusion","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03086993","DB01042,DB00515,DB00441","460612, 2767, 60750","ENSG00000104313","EFO_0000313","ABSENT NA NA","no biomarker"
"29",29,"ADVANCED HEPATOCELLULAR CARCINOMA","absent","NA","NA","NA","ZSP1241","UNK","I","Advanced, Second Line","Safety and tolerability of ZSP1241 in single dose ascending (SAD) and multiple dose ascending (MAD) as measured by assessment of maximum tolerated dose (MTD), dose limiting toxicity (DLT) and treatment emergent adverse events (TEAEs)","NCT03734926","Part 2 cohort A is specific to hepatocellular carcinoma, patients must have Confirmed diagnosis of advanced solid tumors by histological or cytological examination, participants have no effective standard anticancer therapy available or is intolerant to standard anticancer therapy","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03734926","NA","NA","ENSG00000104313","EFO_0009260","ABSENT NA NA","failed drug,no biomarker"
"30",30,"ADVANCED HEPATOCELLULAR CARCINOMA","absent","NA","NA","NA","SHR 1210, APATINIB","PD1, VEGFR2","II","Advanced, First Line, Second Line","Objective Response Rate (ORR)","NCT03463876","Barcelona Clinic Liver Cancer stage Category B or C.","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03463876","NA,DB14765","NA, 45139106","ENSG00000104313","EFO_0009260","ABSENT NA NA","failed drug,no biomarker"
"31",31,"HEPATOCELLULAR CARCINOMA","absent","NA","NA","NA","NIVOLUMAB","UNK","II","First Line","Local recurrence-free survival during a 2-years follow-up after Nivolumab neoadjuvant/adjuvant therapy and EP procedure","NCT03630640","patients will receive electroporation (a form of ablation)","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03630640","DB09035","NA","ENSG00000104313","EFO_0000182","ABSENT NA NA","no biomarker"
"32",32,"ADVANCED HEPATOCELLULAR CARCINOMA","HBsAg","Positive","NA","Protein Expression","PEMBROLIZUMAB","UNK","II","Advanced, First Line, Second Line","Response rate (RR) according to RECIST1.1","NCT03419481","confirmed chronic infection with hepatitis B virus as defined by positivity for HBsAg, For patients who are positive for HBsAg, antiviral therapy for HBV must be given for at least 12 weeks and HBV viral load must be less than 100 IU/mL prior to first dose of study drug. Subjects on active HBV therapy with viral loads under 100 IU/ml should stay on the same therapy throughout study treatment.","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03419481","DB09037","NA","NA","EFO_0009260","HBSAG PROTEIN EXPRESSION POSITIVE","failed biomarker"
"33",33,"LOCALLY ADVANCED OR METASTATIC HEPATOCELLULAR CARCINOMA","absent","NA","NA","NA","APL-501, APL-101","PD1, cMet","I, II","Advanced, Second Line","Dose Limiting Toxicities (Phase 1)","NCT03655613","Other experimental arm with renal cancer","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03655613","NA,NA","NA, NA","ENSG00000104313","EFO_0009260","ABSENT NA NA","failed drug,no biomarker"
"34",34,"UNRESECTABLE OR METASTATIC HEPATOCELLULAR CARCINOMA (III, IIIA, IIIB, IV, IVA, IVB)","absent","NA","NA","NA","BMS-986205, NIVOLUMAB","IDO1, UNK","I, II","Advanced, First Line, Second Line","Incidence of adverse events (AE), Objective response rate (ORR)","NCT03695250","cannot have received more than one systemic HCC therapy","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03695250","NA,DB09035","121328278, NA","ENSG00000104313","EFO_0000702","ABSENT NA NA","no biomarker"
"35",35,"ADVANCED HEPATOCELLULAR CARCINOMA","absent","NA","NA","NA","SHR-1210, FOLFOX4","UNK, UNK","III","Advanced, First Line","Overall Survival","NCT03605706","control is FOLFOX4 or sorafenib. FOLFOX4 is a drug combination","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03605706","NA,NA","NA, NA","ENSG00000104313","EFO_0009260","ABSENT NA NA","failed drug,no biomarker"
"36",36,"HEPATOCELLULAR CARCINOMA","absent","NA","NA","NA","PARA-TOLUENESULFONAMIDE","UNK","II","First Line","Objective Response Rate (ORR)","NCT03447951","experimental groups change drug amount vs tumor volume. Must be Barcelona Clinic Liver Cancer (BCLC) stage B.","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03447951","NA","6269","ENSG00000104313","EFO_0000182","ABSENT NA NA","no biomarker"
"37",37,"UNRESECTABLE HEPATOCELLULAR CARCINOMA","absent","NA","NA","NA","IDARUBICIN, LIPIODOL","UNK, UNK","II","First Line","Percentage of participants presenting a disease control at 4 months","NCT03727633","Has to be disease that is not suitable for resection, ablation or radiofrequency. Cannot be metastatic. Child-Pugh A or B7","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03727633","DB01177,NA","636362, NA","ENSG00000104313","EFO_0000707","ABSENT NA NA","no biomarker"
"38",38,"UNRESECTABLE HEPATOCELLULAR CARCINOMA","absent","NA","NA","NA","BGB-A317","PD1","II","Second Line","Objective Response Rate (ORR) assessed by Independent Review Committee (IRC)","NCT03419897","Must have received at least 1 line of systemic therapy for unresectable HCC","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03419897","NA","NA","ENSG00000104313","EFO_0000707","ABSENT NA NA","failed drug,no biomarker"
"39",39,"UNRESECTABLE HEPATOCELLULAR CARCINOMA","absent","NA","NA","NA","OXALIPLATIN, SORAFENIB","UNK, UNK","II","Advanced, First Line","Progression Free Survival (PFS)","NCT03812770","HAIC: Hepatic arterial infusion chemotherapy with Oxaliplatin. Active Comparator: Sorafenib plus HAIC of FOLFOX. Barcelona clinic liver cancer-stage C","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03812770","DB00526,DB00398","5310940, 406563","ENSG00000104313","EFO_0000707","ABSENT NA NA","no biomarker"
"40",40,"ADVANCED HEPATOCELLULAR CARCINOMA","absent","NA","NA","NA","REGORAFENIB, PEMBROLIZUMAB","UNK, UNK","I","Advanced, First Line","Incidence of treatment-emergent adverse event(TEAEs), Severity of TEAEs, se Limiting Toxicities(DLTs)","NCT03347292","Barcelona Clinic Liver Cancer (BCLC) stage B or C","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03347292","DB08896,DB09037","11167602, NA","ENSG00000104313","EFO_0009260","ABSENT NA NA","no biomarker"
"41",41,"ADVANCED HEPATOCELLULAR CARCINOMA","absent","NA","NA","NA","CABOZANTINIB, ATEZOLIZUMAB","UNK, UNK, UNK","III","Advanced, First Line","Duration of Progression Free Survival (PFS) for the experimental arm vs. the control arm , Duration of Overall Survival (OS) for the experimental arm vs. the control arm","NCT03755791","Active comparator: Sorafenib. Barcelona Clinic Liver Cancer (BCLC) stage Category B or C.","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03755791","DB08875,DB11595","25102846, NA","ENSG00000104313","EFO_0009260","ABSENT NA NA","no biomarker"
"42",42,"ADVANCED HEPATOCELLULAR CARCINOMA","absent","NA","NA","NA","LENVATINIB, OXALIPLATIN, FLUOROURACIL, LEUCOVORIN","UNK, UNK, UNK, UNK","III","Advanced, First Line","Overall survival","NCT03775395","Active comparator: Oxaliplatin, fluorouracil, leucovorin and Sorafenib. HAIC is Hepatic arterial infusion chemotherapy with Oxaliplatin, fluorouracil, leucovorin. Barcelona clinic liver cancer-stage C","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03775395","DB09078,DB00526,DB00544,DB00650","11237762, 5310940, 3385, 135403647","ENSG00000104313","EFO_0009260","ABSENT NA NA","no biomarker"
"43",43,"ADVANCED HEPATOCELLULAR CARCINOMA","absent","NA","NA","NA","PT-112","UNK","II","Advanced, Second Line","Adverse Event (AE), Dose Limited Toxicity (DLT), AE, Disease Control Rate (DCR). Barcelona Clinic Liver Cancer (BCLC) staging: Stage C","NCT03439761","HCC is tested in the second phase of this trial","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03439761","NA","3001152","ENSG00000104313","EFO_0009260","ABSENT NA NA","no biomarker"
"44",44,"ADVANCED HEPATOCELLULAR CARCINOMA","absent","NA","NA","NA","LENVATINIB, PEMBROLIZUMAB","UNK, UNK","III","Advanced, First Line","Progression-free Survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1), Overall Survival (OS)","NCT03713593","Active Comparator: lenvatinib plus placebo. Has Barcelona Clinic Liver Cancer (BCLC) Stage C disease, or BCLC Stage B disease not amenable to locoregional therapy or refractory to locoregional therapy, and not amenable to a curative treatment approach","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03713593","DB09078,DB09037","11237762, NA","ENSG00000104313","EFO_0009260","ABSENT NA NA","no biomarker"
"45",45,"LOCALLY ADVANCED OR METASTATIC HEPATOCELLULAR","absent","NA","NA","NA","ATEZOLIZUMAB, BEVACIZUMAB","UNK, UNK","III","Advanced, First Line","Overall Survival (OS), ogression Free Survival (PFS) as Determined by an Independent Review Facility (IRF) According to Response Evalutaion Criteria in Solid Tumors (RECIST) v1.1","NCT03434379","Active comparator: Sorafenib","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03434379","DB11595,DB00112","NA, NA","ENSG00000104313","EFO_0009709","ABSENT NA NA","no biomarker"
"46",46,"HEPATOCELLULAR CARCINOMA","absent","NA","NA","NA","MIV-818","UNK","II","First Line, Second Line","Number of participants with treatment related AEs as assessed by CTCAE v5.0","NCT03781934","HCC in phase 2a cohort","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03781934","NA","NA","ENSG00000104313","EFO_0000182","ABSENT NA NA","failed drug,no biomarker"
"47",47,"URESECTABLE OR NON-ADVANCED HEPATOCELLULAR CARCINOMA","absent","NA","NA","NA","LENVATINIB, NIVOLUMAB","UNK, UNK","I","First Line","Part 1: Number of Participants with Dose-Limiting Toxicities (DLTs), Part 1 and Part 2: Number of Participants with Any Serious and/or Non-serious Adverse Event","NCT03418922","Part 1: HCC for which no other appropriate therapy is available; Part 2: No prior systemic therapy for advanced/unresectable HCC","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03418922","DB09078,DB09035","11237762, NA","ENSG00000104313","EFO_0009260","ABSENT NA NA","no biomarker"
"48",48,"HEPATOCELLULAR CARCINOMA","absent","NA","NA","NA","LENVATINIB","UNK","III","First Line","RFS","NCT04053972","Control group has no intervention. Patients must receive hepatectomy and have microvascular invasion following surgery","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT04053972","DB09078","11237762","ENSG00000104313","EFO_0000182","ABSENT NA NA","no biomarker"
"49",49,"LOCALLY ADVANCED OR METASTATIC HEPATOCELLULAR","absent","NA","NA","NA","GNS561","UNK","I, II","Advanced, First Line, Second Line","Dose-Limiting Toxicity","NCT03316222","must be deemed not appropriate for curative therapy","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03316222","NA","NA","ENSG00000104313","EFO_0009709","ABSENT NA NA","failed drug,no biomarker"
"50",50,"INTRAHEPATIC CHOLANGIOCARCINOMA","absent","NA","NA","NA","GNS561","UNK","I, II","Advanced, First Line, Second Line","Dose-Limiting Toxicity","NCT03316222","must be deemed not appropriate for curative therapy","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03316222","NA","NA","ENSG00000104313","EFO_1001961","ABSENT NA NA","failed drug,no biomarker"
"51",51,"ADVANCED HEPATOCELLULAR CARCINOMA","absent","NA","NA","NA","SORAFENIB, OXALIPLATIN","UNK, UNK","III","Advanced, First Line","Overall survival","NCT03468231","Active Comparator is sorafenib plus HAIC of FOLFOX (administration of Oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries). Patients must be diagnosed with major or main portal vein invasion (Vp3 or Vp4). Uses hepatic arterial infusion chemotherapy (HAIC)","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03468231","DB00398,DB00526","406563, 5310940","ENSG00000104313","EFO_0009260","ABSENT NA NA","no biomarker"
"52",52,"HEPATOCELLULAR CARCINOMA","absent","NA","NA","NA","PEMBROLIZUMAB, DOXORUBICIN","UNK, UNK","I, II","First Line","Incidence of treatment-emergent adverse events (safety and tolerability)","NCT03397654","Trans-arterial chemoembolization (TACE) using doxorubicin solution (60 mg dose) and gelatin sponge particles; followed, at least 30 or 45 days later, by pembrolizumab solution (200 mg dose) every 3 weeks for a maximum of 1 year. Patients must be ineligible for surgical resection or liver transplantation.","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03397654","DB09037,DB00997","NA, 443939","ENSG00000104313","EFO_0000182","ABSENT NA NA","no biomarker"
"53",53,"ADVANCED HEPATOCELLULAR CARCINOMA","absent","NA","NA","NA","NIVOLUMAB, IPILIMUMAB","UNK, UNK","II","Advanced, First Line, Second Line","the percentage of subjects with tumor shrinkage after study drug treatment","NCT03510871","Cannot have evidence of extra-hepatic metastases.","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03510871","DB09035,DB06186","NA, NA","ENSG00000104313","EFO_0009260","ABSENT NA NA","no biomarker"
"54",54,"ADVANCED HEPATOCELLULAR CARCINOMA","absent","NA","NA","NA","CABOZANTINIB","UNK","II","Advanced, Second Line","24-Week Progression-Free Survival Rate (PFSR)","NCT03586973","Participants who have received 1 or 2 prior anticancer therapies for advanced HCC, Cohort A: participants who have received prior sorafenib, Cohort B: participants who have not received prior sorafenib. Note: Additional prior systemic therapies used as adjuvant or local therapy are allowed.","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03586973","DB08875","25102846","ENSG00000104313","EFO_0009260","ABSENT NA NA","no biomarker"
"55",55,"ADVANCED HEPATOCELLULAR CARCINOMA","absent","NA","NA","NA","PD1 MAB, POLYIC","PD1, UNK","II","Advanced, Second Line","Objective response rate (ORR)","NCT03732547","barcelona stage C, or stage B but resistant/recurrent to prior local treatment","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03732547","NA,NA","NA, NA","ENSG00000104313","EFO_0009260","ABSENT NA NA","failed drug,no biomarker"
"56",56,"ADVANCED UNRESECTABLE HEPATOCELLULAR CARCINOMA","HBV","Positive","NA","missing","ATG-008","UNK","II","Advanced, Second Line","Cmax, AUC, The incidence of treatment emergent adverse events (TEAEs) & SAE assessed by CTCAE v4.03 , ORR","NCT03591965","must have Who Have Received at Least One Prior Line of Systemic Therapy , be HBV+, and Unresectable stage B or C HCC according to the Barcelona Clinic Liver Cancer (BCLC) staging.","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03591965","NA","58298316","ENSG00000112773","EFO_0009260","HBV MISSING POSITIVE","pass"
"57",57,"ADVANCED HEPATOCELLULAR CARCINOMA","absent","NA","NA","NA","PEMBROLIZUMAB","UNK","II","Advanced, Second Line","Overall response rate","NCT03316872","being tested in combination with Stereotactic Body Radiotherapy (SBRT). First line therapy with sorafenib. Cannot have two lines of treatment","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03316872","DB09037","NA","ENSG00000104313","EFO_0009260","ABSENT NA NA","no biomarker"
"58",58,"LOCALLY ADVANCED UNRESECTABLE OR METASTATIC COMBINED HEPATOCELLULAR-CHOLANGIOCARCINOMA, LOCALLY ADVANCED UNRESECTABLE OR METASTATIC INTRAHEPATIC CHOLANGIOCARCINOMA","FGFR2","Positive","NA","mutation/gene fusion/amplification","DERAZANTINIB","UNK","II","Advanced, Second Line","Substudy 1: Anti-cancer activity of derazantinib by Objective Response Rate (ORR)","NCT03230318","Substudy 1: FGFR2 gene fusion, Substudy 2: FGFR2 mutation status","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03230318","DB14889","46834118","ENSG00000066468","EFO_0009260","FGFR2 MUTATION/GENE FUSION/AMPLIFICATION POSITIVE","pass"
"59",59,"LOCALLY ADVANCED UNRESECTABLE OR METASTATIC CHOLANGIOCARCINOMA","absent","NA","NA","NA","CISPLATIN, GEMCITABINE, COPANLISIB","UNK, UNK, UNK","II","Advanced, First Line","Progression Free Survival (PFS)","NCT02631590","Must have histologically or cytologically documented carcinoma primary to the intra- or extra-hepatic biliary system or gall bladder with clinical and/or radiologic evidence of unresectable, locally advanced or metastatic disease. Patients with ampullary carcinoma are not eligible.","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT02631590","DB00515,DB00441,DB12483","2767, 60750, 135565596","ENSG00000104313","EFO_0009260","ABSENT NA NA","no biomarker"
"60",60,"LOCALLY ADVANCED UNRESECTABLE OR METASTATIC HEPATOCELLULAR CARCINOMA","AFP","Positive","NA","Protein Expression","RAMUCIRUMAB, MEDI4736","UNK","I","Advanced, Second Line","Number of Participants with Dose Limiting Toxicities (DLTs)","NCT02572687","Other cancers in trial, HCC in experimental arm. Has histopathologically or cytologically confirmed HCC, Child-Pugh Class A, with documented disease progression during or after discontinuation of sorafenib therapy, or intolerance of sorafenib therapy,","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT02572687","DB05578,NA","NA, NA","ENSG00000081051","EFO_0009260","AFP PROTEIN EXPRESSION POSITIVE","pass"
"61",61,"HEPATOCELLULAR CARCINOMA","absent","NA","NA","NA","FOLFOX","UNK","III","First Line","Overall survival","NCT02738697","FOLFOX is a combination of drugs, not listed. Comparator is just no follow up treatment. Must have resection surgery with  microvessels invasion following","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT02738697","NA","135659064","ENSG00000104313","EFO_0000182","ABSENT NA NA","no biomarker"
"62",62,"ADVANCED HEPATOCELLULAR CARCINOMA","absent","NA","NA","NA","SORAFENIB","UNK","III","Advanced, First Line","overall survival (OS), Event free survival","NCT02971696","must be HCC patients whose etiology from HCV genotype 4. Sorafenib vs best supportive care.","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT02971696","DB00398","406563","ENSG00000104313","EFO_0009260","ABSENT NA NA","no biomarker"
"63",63,"ADVANCED HEPATOCELLULAR CARCINOMA","absent","NA","NA","NA","DONAFENIB","tyrosine kinase","II, III","Advanced, First Line","Overall Survival","NCT02645981","active comparator is sorafenib. donafenib, an oral multikinase inhibitor that targets Raf kinase and receptor tyrosine kinases","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT02645981","DB15414","25191001","ENSG00000104313","EFO_0009260","ABSENT NA NA","no biomarker"
"64",64,"ADVANCED HEPATOCELLULAR CARCINOMA","absent","NA","NA","NA","GENEXOL-PM","UNK","II","Advanced, First Line","Progression-free survival rate at 6 months","NCT03008512","must have Previous sorafenib treatment for at least 14 days and discontinuation of sorafenib treatment prior to inclusion, Barcelona Clinic Liver Cancer (BCLC) stage C or BCLC stage B disease not amenable to locoregional therapy or refractory to locoregional therapy","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03008512","NA","36314","ENSG00000104313","EFO_0009260","ABSENT NA NA","no biomarker"
"65",65,"HEPATOCELLULAR CARCINOMA","AFP","Positive","NA","Protein Expression","SORAFENIB","UNK","IV","First Line","overall survival of 1 year, overall survival of 3 year","NCT03178656","Patients with HCC and Portal Vein tumor Thrombus (PVTT). Comparator is resection. Must be Patients with a solitary tumor or multiple tumor which are resectable. 4. Patients without Hepatic vein or bile duct invasion and extrahepatic metastasis","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03178656","DB00398","406563","ENSG00000081051","EFO_0000182","AFP PROTEIN EXPRESSION POSITIVE","pass"
"66",66,"ADVANCED HEPATOCELLULAR CARCINOMA","absent","NA","NA","NA","5-FLUOROURACIL, OXALIPLATIN, LEUCOVORIN","UNK, UNK, UNK","II","Advanced, First Line","Tumor response","NCT02987699","Different experimental arms changing dosage of chemotherapy. Administered by using HAI. Must have been diagnosed with major or main portal vein invasion","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT02987699","DB00544,DB00526,DB00650","3385, 5310940, 135403647","ENSG00000104313","EFO_0009260","ABSENT NA NA","no biomarker"
"67",67,"ADVANCED HEPATOCELLULAR CARCINOMA","absent","NA","NA","NA","SHR-1210","UNK","II","Advanced, Second Line","Objective Response Rate per RECIST 1.1, Overall Survival Rate at 6-month","NCT02989922","Failed or intolerable to at least one prior systemic treatment for advanced HCC","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT02989922","NA","NA","ENSG00000104313","EFO_0009260","ABSENT NA NA","failed drug,no biomarker"
"68",68,"ADVANCED HEPATOCELLULAR CARCINOMA","absent","NA","NA","NA","PDR001, INC280","UNK, UNK","I, II","Advanced, Second Line","Number of participants with Dose Limiting Toxicities (DLTs), Overall response rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST v1.1)","NCT02795429","Patients must have received prior systemic sorafenib treatment for HCC with documented progression during or after discontinuation of sorafenib treatment (for France only: patients must have received at least 8 weeks of prior sorafenib treatment), or are intolerant to sorafenib (defined as documented Grade 3 or 4 adverse events that led to sorafenib discontinuation),.","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT02795429","NA,NA","NA, 25145656","ENSG00000104313","EFO_0009260","ABSENT NA NA","failed drug,no biomarker"
"69",69,"HEPATOCELLULAR CARCINOMA","absent","NA","NA","NA","OXALIPLATIN, LEUCOVORIN, 5-FU","UNK, UNK, UNK","UNK","First Line","early recurrence","NCT02813096","Trial to prevent postoperative recurrence, especially in HCC patients with portal vein tumor thrombus (PVTT). folfox4 chemotherapy regimen. patients without recurrence within the first month after curative resection are eligible","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT02813096","DB00526,DB00650,DB00544","5310940, 135403647, 3385","ENSG00000104313","EFO_0000182","ABSENT NA NA","no biomarker"
"70",70,"HEPATOCELLULAR CARCINOMA","absent","NA","NA","NA","CISPLATIN, LIPIODOL","UNK","II","First Line","Time to progression (TTP)","NCT03268499","Active Comparator: Lipiodol-cisplatin emulsion. Trial looks at difference between emulsion and suspension. Deleivered using TACE, BCLC A or B, can have a resection or be uneligible, also uneligible for ablation","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03268499","DB00515,NA","2767, NA","ENSG00000104313","EFO_0000182","ABSENT NA NA","no biomarker"
"71",71,"HEPATOCELLULAR CARCINOMA","absent","NA","NA","NA","CAROTUXIMAB, SORAFENIB","UNK, UNK","I, II","First Line","Maximum Tolerated Dose of TRC105 in Combination with Sorafenib (Phase 1b), Estimate the ORR of patients with unresectable hepatocellular carcinoma given TRC105 and sorafenib (Phase 2)","NCT02560779","Patients must have disease that is not amenable to potentially curative resection or ablative techniques or that has recurred following ablative techniques. In addition, disease must not be amenable to transhepatic arterial chemoembolization (TACE) or must have progressed on TACE. Patients must not be candidates for liver transplantation.","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT02560779","DB06322,DB00398","NA, 406563","ENSG00000104313","EFO_0000182","ABSENT NA NA","no biomarker"
"72",72,"LOCALLY ADVANCED HEPATOCELLULAR CARCINOMA","absent","NA","NA","NA","SORAFENIB, CAPECITABINE, OXALIPLATIN","UNK, UNK, UNK","II","Advanced, First Line","Resectability","NCT03578874","Drug combination called SECOX. Must be Fit enough to undergo surgery to resect the primary liver tumour","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03578874","DB00398,DB01101,DB00526","406563, 60953, 5310940","ENSG00000104313","EFO_0009260","ABSENT NA NA","no biomarker"
"73",73,"ADVANCED HEPATOCELLULAR CARCINOMA","absent","NA","NA","NA","DURVALUMAB, TREMELIMUMAB","UNK, UNK","II","Advanced, Second Line","Progression free survival","NCT02821754","Patients must have disease that is not amenable to potentially curative resection, transplantation or ablation. HCC patients must have progressed on, been intolerant to, or refused prior sorafenib therapy. Testing drug combinations with TACE, cryoablation, radiofrequency ablation and alone","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT02821754","DB11714,DB11771","NA, NA","ENSG00000104313","EFO_0009260","ABSENT NA NA","no biomarker"
"74",74,"ADVANCED BILIARY TRACT CANCER","absent","NA","NA","NA","DURVALUMAB, TREMELIMUMAB","UNK, UNK","II","Advanced, Second Line","Progression free survival","NCT02821754","Patients must have disease that is not amenable to potentially curative resection, transplantation or ablation. Patients with BTC must have received, been intolerant of or refused at least one line of chemotherapy. Testing drug combinations with TACE, cryoablation, radiofrequency ablation and alone","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT02821754","DB11714,DB11771","NA, NA","ENSG00000104313","MONDO_0003060","ABSENT NA NA","no biomarker"
"75",75,"ADVANCED UNRESECTABLE HEPATOCELLULAR CARCINOMA","absent","NA","NA","NA","CISPLATIN, 5-FLUOROURACIL","UNK, UNK","II","Advanced, Second Line","Objective tumor response","NCT02967887","Using hepatic arterial infusion chemotherapy. Patients with advanced hepatocellular carcinoma who cannot be treated with surgery, transplantation, RFA, or TACE. Must have been intolerant or progressed on sorafenib. Cannot have extrahepatic tumors","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT02967887","DB00515,DB00544","2767, 3385","ENSG00000104313","EFO_0009260","ABSENT NA NA","no biomarker"
"76",76,"ADVANCED OR METASTATIC HEPATOCELLULAR CARCINOMA","absent","NA","NA","NA","SORAFENIB, CAPECITABINE, OXALIPLATIN","UNK, UNK, UNK","II","Advanced, First Line","Time to progression (TTP)","NCT02716766","active comparator is sorafenib. Drug combination is called SECOX","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT02716766","DB00398,DB01101,DB00526","406563, 60953, 5310940","ENSG00000104313","EFO_0009260","ABSENT NA NA","no biomarker"
"77",77,"ADVANCED HEPATOCELLULAR CARCINOMA","absent","NA","NA","NA","SORAFENIB, OXALIPLATIN, FLUOROURACIL, LEUCOVORIN","UNK, UNK, UNK, UNK","III","Advanced, First Line","Overall survival","NCT02774187","active comparator is sorafenib. Oxaliplatin, fluorouracil, and leucovorin is administered with HAIC. Combination of Oxaliplatin, fluorouracil, and leucovorin is the FOLFOX protocol. Patients must have portal vein tumor thrumbus","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT02774187","DB00398,DB00526,DB00544,DB00650","406563, 5310940, 3385, 135403647","ENSG00000104313","EFO_0009260","ABSENT NA NA","no biomarker"
"78",78,"UNRESECTABLE HEPATOCELLULAR CARCINOMA","absent","NA","NA","NA","CC-122, NIVOLUMAB","UNK, UNK","I, II","First Line, Second Line","Dose Limiting Toxicity (DLT) , Adverse Events (AEs), Overall Response Rate (ORR) - Phase 2","NCT02859324","Subjects who have progressed after or were intolerant to no more than 2 previous systemic therapies for unresectable HCC, or are naïve to systemic therapy.","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT02859324","NA,DB09035","24967599, NA","ENSG00000104313","EFO_0000707","ABSENT NA NA","no biomarker"
"79",79,"MIDDLE-ADVANCED PRIMARY HEPATOCELLULAR CARCINOMA","absent","NA","NA","NA","PIRARUBICIN, ARSENIC TRIOXIDE","UNK, UNK","II","Advanced, First Line","Progression free survival","NCT02956772","TACE with the pirarubicin. The active comparator is just the pirarubicin TACE treatment alone. Subject has primary middle-advanced liver cancer of Barcelona Clinic Liver Cancer stages B/C inappropriate for surgical resection or other locoregional therapy and still presents with tumor lesions in the liver","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT02956772","DB11616,DB01169","45358767, NA","ENSG00000104313","EFO_0009260","ABSENT NA NA","no biomarker"
"80",80,"ADVANCED HEPATOCELLULAR CARCINOMA","absent","NA","NA","NA","H3B-6527","UNK","I","Advanced, Second Line","Number of Participants with Dose-limiting Toxicities (DLTs), Number of Participants with Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)","NCT02834780","Must have had at least one prior standard-of-care therapy, unless contraindicated.","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT02834780","DB15169","118029202","ENSG00000104313","EFO_0009260","ABSENT NA NA","no biomarker"
"81",81,"URESECTABLE HEPATOCELLULAR CARCINOMA","absent","NA","NA","NA","LENVATINIB","UNK","I","First Line, Second Line","Mean maximum observed concentration (Cmax), Mean time at which the highest drug concentration occurs (tmax), Mean area under the concentration-time curve from zero time to time of last quantifiable concentration (AUC(0-t)), Mean maximum observed concentration at steady-state (Css,max ), Mean minimum observed concentration at steady-state (Css,min), Average steady-state concentration (Css,av) , Mean time at which the highest drug concentration occurs at steady-state (tss,max) , Mean area under the concentration-time curve over the dosing interval on multiple dosing (AUC(0-τ))","NCT02953743","Participants categorized to stage B (not applicable for transarterial chemoembolization [TACE]) or stage C based on Barcelona Clinic Liver Cancer (BCLC) staging system","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT02953743","DB09078","11237762","ENSG00000104313","EFO_0000707","ABSENT NA NA","no biomarker"
"82",82,"ADVANCED HEPATOCELLULAR CARCINOMA","absent","NA","NA","NA","PEMBROLIZUMAB","UNK","III","Advanced, Second Line","Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) , Overall Survival (OS)","NCT02702401","comparator is placebo. Both trials have Best supportive care. First line treatment must be with sorafenib","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT02702401","DB09037","NA","ENSG00000104313","EFO_0009260","ABSENT NA NA","no biomarker"
"83",83,"LOCALLY ADVANCED OR METASTATIC HEPATOCELLULAR CARINOMA","AFP","Positive","NA","Protein Expression","BAVITUXIMAB, SORAFENIB","UNK/UNK","I, II","Advanced, First Line, Second Line","Safety as measured by the number of participants with adverse events, Time to Progression (phase II)as measured by abdominal magnetic resonance imaging","NCT01264705","Advanced HCC is defined as disease that is not amenable to surgical resection or orthotopic liver transplantation or is metastatic in nature, Prior adjuvant therapy with sorafenib or other Raf/MEK/RAS or VEGFR inhibitor","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT01264705","DB05136,DB00398","NA, 406563","ENSG00000081051","EFO_0009709","AFP PROTEIN EXPRESSION POSITIVE","pass"
"84",84,"ADVANCED HEPATOCELLULAR CARCINOMA","RB","Positive","NA","Protein Expression","PD-0332991","CDK4/CDK6","II","Advanced, First Line","Time to Disease Progression","NCT01356628","No other active malignancy requiring treatment in the last 3 years other than adequately treated non-melanomatous skin cancer, adequately treated cervical carcinoma in-situ, superficial adequately treated bladder cancer or prostatic intraepithelial neoplasia without evidence of prostate cancer.","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT01356628","NA","5330286","ENSG00000139687","EFO_0009260","RB PROTEIN EXPRESSION POSITIVE","pass"
"85",85,"HEPATOCELLULAR CARCINOMA","Absent","NA","NA","NA","TRC105","CD105","II","Advanced, Second Line","Time to Tumor Progression (TTP) for TRC105 in Hepatocellular Carcinoma","NCT01375569","Not eligible for a liver transplant","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT01375569","NA","NA","ENSG00000104313","EFO_0000182","ABSENT NA NA","failed drug"
"86",86,"ADVANCED HEPATOCELLULAR CARCINOMA","Absent","NA","NA","NA","LENALIDOMIDE","UNK","II","Advanced, Second Line","disease stabilization","NCT01545804","Acceptable first-line molecular targeted therapies include (1) sorafenib monotherapy and sorafenib-based combination; (2) anti-angiogenic therapy including brivanib, linifanib, pazopanib, bevacizumab, dovitinib (TKI258), and vargatef (BIBF1120).","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT01545804","DB00480","216326","ENSG00000104313","EFO_0009260","ABSENT NA NA","pass"
"87",87,"ADVANCED LIVER CANCER","Absent","NA","NA","NA","BEVACIZUMAB, ERLOTINIB","VEGF, UNK","II","Advanced, Second Line","Number of Patients with Progression Free Survival (PFS) at 16 weeks","NCT01180959","First line treatment must be with with sorafenib, not amenable to curative resection","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT01180959","DB00112,DB00530","NA, 176871","ENSG00000104313","MONDO_0002691","ABSENT NA NA","pass"
"88",88,"PROGRESSIVE HEPATOCELLULAR CARCINOMA","Absent","NA","NA","NA","OPB-31121","UNK","I, II","Advanced, Second Line","Subjects With Treatment Emergent Adverse Events, Number of Participants Who Experienced Dose-Limiting Toxicities (DLTs)","NCT01406574","Patients unresponsive to standard therapy or for whom standard therapy is intolerable, or for whom there is no appropriate therapy","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT01406574","NA","NA","ENSG00000104313","EFO_0000707","ABSENT NA NA","failed drug"
"89",89,"METASTATIC HEPATOCELLULAR CARCINOMA","Absent","NA","NA","NA","AXITINIB","UNK","II","Advanced, Second Line","Response rate","NCT01334112","Previous treatment with tyrosine kinase inhibitors or antiangiogenic drugs","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT01334112","DB06626","6450551","ENSG00000104313","EFO_0000702","ABSENT NA NA","pass"
"90",90,"ADVANCED OR METASTATIC HEPATOCELLULAR CARCINOMA","AFP","Positive","NA","Protein Expression","EVEROLIMUS, PASIREOTIDE","UNK, UNK","II","Advanced, Second Line","Time to Progression (TTP)","NCT01488487","Prior systemic therapy limited to sorafenib that was discontinued due to intolerance. Patients must undergo at least a 4-week washout prior to enrollment.","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT01488487","DB01590,DB06663","6442177, 9941444","ENSG00000081051","EFO_0009260","AFP PROTEIN EXPRESSION POSITIVE","pass"
"91",91,"UNRESECTABLE LOCALLY ADVANCED OR METASTATIC HCC","Absent","NA","NA","NA","SORAFENIB, E7050","UNK, UNK","I, II","Advanced, First Line","Safety Parameters-Adverse Event (AEs), Safety Parameter-Concomitant Meds, Safety Parameter- Clinical Laboratory Evaluations, Safety Parameter-ECGS, Safety Parameters-Vital signs, Safety Parameters- ECOG PS","NCT01271504","NA","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT01271504","DB00398,NA","406563, 16118392","ENSG00000104313","EFO_0009709","ABSENT NA NA","pass"
"92",92,"ADVANCED HEPATOCELLULAR CARCINOMA","Absent","NA","NA","NA","ADI-PEG 20","UNK","III","Advanced, Second Line","Overall survival","NCT01287585","Best Supportive Care","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT01287585","DB06592","NA","ENSG00000104313","EFO_0009260","ABSENT NA NA","pass"
"93",93,"HEPATOCELLULAR CARCINOMA","Absent","NA","NA","NA","TYROSERLEUTIDE, MITOMYCIN, FLUOROURACIL","UNK","III","First Line","RFS(Recurrence Free Survival)","NCT01489566","Subject underwent a complete resection of hepatocellular carcinoma (confirmed by pathology)","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT01489566","NA,DB00305,DB00544","10045387, 5746, 3385","ENSG00000104313","EFO_0000182","ABSENT NA NA","pass"
"94",94,"UNRESECTABLE HEPATOCELLULAR CARCINOMA","Absent","NA","NA","NA","AXITINIB","UNK","II","Advanced, First Line","Two-year survival rate ","NCT01352728","Must receive transarterial chemoembolization with addition of axitinib","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT01352728","DB06626","6450551","ENSG00000104313","EFO_0000707","ABSENT NA NA","pass"
"95",95,"ADVANCED HEPATOCELLULAR CARCINOMA","Absent","NA","NA","NA","SIR-SPHERE","UNK","III","Advanced, First Line","Median overall survival time","NCT01482442","must not be eligible for surgical resection or transplantation, first line for advanced disease, can have prior treatment for primary tumor","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT01482442","NA","NA","ENSG00000104313","EFO_0009260","ABSENT NA NA","failed drug"
"96",96,"ADVANCED HEPATOCELLULAR CARCINOMA","Absent","NA","NA","NA","AG-013736","UNK","II","Advanced, Second Line","disease stabilization","NCT01273662","Inoperable tumor(s) and no applicable curative therapy. Not amenable to loco-regional , first line treatment must have been with sorafenib","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT01273662","NA","6450551","ENSG00000104313","EFO_0009260","ABSENT NA NA","pass"
"97",97,"ADVANCED HEPATOCELLULAR CARCINOMA","Absent","NA","NA","NA","TS-1, OXALIPLATIN","UNK, UNK","II","Advanced, First Line, Second Line","Time to progression (TTP)","NCT01429961","TS-1, Oxaliplatin (Drug combination called SOX), only second line treatment for those who have been treated with sorafenib as their first line treatment, presence of extrahepatic measurable lesion","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT01429961","NA,DB00526","5386, 5310940","ENSG00000104313","EFO_0009260","ABSENT NA NA","pass"
"98",98,"ADVANCED HEPATOCELLULAR CARCINOMA","Absent","NA","NA","NA","MAPATUMUMAB, SORAFENIB","TRAILR1, UNK","I, II","Advanced, First Line","Time to Progression-Blinded Independent Central Review (BICR) Assessment","NCT01258608","Barcelona Clinic Liver Cancer (BCLC) advanced stage (C) hepatocellular carcinoma, or BCLC intermediate stage (B) hepatocellular carcinoma if treatment with transarterial chemoembolization is not considered appropriate","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT01258608","NA,DB00398","NA, 406563","ENSG00000104313","EFO_0009260","ABSENT NA NA","failed drug"
"99",99,"ADVANCED HEPATOCELLULAR CARCINOMA","Absent","NA","NA","NA","S-1, LEUCOVORIN","UNK, UNK","II","First Line, Second Line","DCR","NCT01533324","NA","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT01533324","NA,DB00650","5462310, 135403647","ENSG00000104313","EFO_0009260","ABSENT NA NA","pass"
"100",100,"OR UNRESECTABLE HEPATOCELLULAR CARCINOMA","Absent","NA","NA","NA","RO5323441, SORAFENIB","UNK, UNK","I","Advanced, First Line","Part I : Safety/dose-limiting toxicity: Incidence of adverse events, Part I: Determination of recommended Part II dose, Part II: Safety/tolerability: Incidence of adverse events","NCT01308723","Excludes patients with prior systemic treatment for metastatic hepatocellular carcinoma or patients who had tumor removed","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT01308723","NA,DB00398","NA, 406563","ENSG00000104313","EFO_0000707","ABSENT NA NA","failed drug"
"101",101,"HEPATOCELLULAR CARCINOMA","Absent","NA","NA","NA","TRC 105, SORAFENIB","UNK, UNK","I, II","Advanced, First Line, Second Line","Phase I: Maximum Tolerated Dose (MTD) of TRC105 When Given With Standard-dose Sorafenib for Hepatocellular Cancer (HCC), Phase II: Time to Progression (TTP) for the Combination of TR105 With Sorafenib in Hepatocellular Cancer (HCC)","NCT01306058","Second Line treatment only if first line treatment was with sorafenib, Patients must have disease that is not amenable to potentially curative resection or ablative techniques. In addition, disease must not be amenable to or have progressed on transhepatic arterial chemoembolization (TACE). Patients must not be considered potential candidates for liver transplantation. This determination will be made after hepatobiliary surgical input at the NCI multidisciplinary conference.","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT01306058","NA,DB00398","NA, 406563","ENSG00000104313","EFO_0000182","ABSENT NA NA","failed drug"
"102",102,"HEPATOCELLULAR CARCINOMA","Absent","NA","NA","NA","ETHIODIZED OIL, DOXORUBICIN","UNK, UNK","III","First Line","disease-free survival","NCT01966133","Other Name: doxorubicin-lipiodol mixture, HCC patients received curative hepatectomy with negative resection margin, Drugs delievered using Transarterial chemoembolisation","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT01966133","DB00965,DB00997","NA, 443939","ENSG00000104313","EFO_0000182","ABSENT NA NA","pass"
"103",103,"HEPATIC CARCINOMA","Absent","NA","NA","NA","HUAIER GRANULE","UNK","IV","First Line","Incidence of Recurrence and Metastasis After Hepatectomy","NCT01770431","Radical hepatectomy has been performed for hepatocellular carcinoma, Barcelona clinic liver cancer(BCLC) stage A or B","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT01770431","NA","NA","ENSG00000104313","EFO_0000313","ABSENT NA NA","failed drug"
"104",104,"ADVANCED HEPATOCARCINOMA","Absent","NA","NA","NA","PRAVASTATIN, SORAFENIB","UNK, UNK","II","Advanced, First Line, Second Line","Advanced Hepatocarcinoma","NCT01418729","NA","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT01418729","DB00175,DB00398","16759173, 406563","ENSG00000104313","EFO_0009260","ABSENT NA NA","pass"
"105",105,"LIVER CANCER","absent","NA","NA","NA","SORAFENIB TOSYLATE","NA","II","First line","To assess anti-tumor activity of neoadjuvant sorafenib tosylate in tumor samples from patients with resectable hepatocellular carcinoma","NCT01182272","along with surgery","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT01182272","NA","406563","ENSG00000104313","MONDO_0002691","ABSENT NA NA","no biomarker"
"106",106,"ADVANCED HEPATOCELLULAR CARCINOMA","absent","NA","NA","NA","PEG-BCT-100","NA","I/II","Advanced, Second line","Tumor response","NCT01092091","NA","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT01092091","NA","NA","ENSG00000104313","EFO_0009260","ABSENT NA NA","failed drug,no biomarker"
"107",107,"ADVANCED HEPATOCELLULAR CARCINOMA","AFP","Positive","NA","Protein Expression","SORAFENIB TOSYLATE, VORINOSTAT","NA","I","Advanced, Second line","Determine the appropriate Doses for the combination of sorafenib tosylate and vorinostat appropriate for phase II study in hepatocellular carcinoma (HCC)","NCT01075113","NA","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT01075113","NA,DB02546","406563, 5311","ENSG00000081051","EFO_0009260","AFP PROTEIN EXPRESSION POSITIVE","pass"
"108",108,"HEPATOCELLULAR CARCINOMA","absent","NA","NA","NA","SUNITINIB MALATE","NA","II,III","First line","Overall survival, Occurrence of severe bleeding or liver failure","NCT01164202","must be done with chemoembolization","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT01164202","NA","6456015","ENSG00000104313","EFO_0000182","ABSENT NA NA","no biomarker"
"109",109,"LIVER CANCER","absent","NA","NA","NA","DOXORUBICIN-ELUTING BEADS, SORAFENIB TOSYLATE","NA","III","First line","To determine whether the addition of sorafenib tosylate to transarterial chemoembolization (TACE) with doxorubicin-eluting beads, compared to TACE alone, prolongs progression-free survival of patients with unresectable hepatocellular carcinoma.","NCT01324076","cannont be removed by surgery, inlcudes cheoembolization","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT01324076","NA,NA","NA, 406563","ENSG00000104313","MONDO_0002691","ABSENT NA NA","failed drug,no biomarker"
"110",110,"HEPATOCELLULAR CARCINOMA","absent","NA","NA","NA","SORAFENIB TOSYLATE, PRAVASTATIN SODIUM","NA","III","Advanced, Second line","To evaluate the effects of sorafenib tosylate and pravastatin versus sorafenib tosylate alone on overall survival of patients with hepatocellular carcinoma and Child-Pugh Class A cirrhosis.","NCT01075555","must also have cirrhosis","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT01075555","NA,NA","406563, 16759173","ENSG00000104313","EFO_0000182","ABSENT NA NA","no biomarker"
"111",111,"ADVANCED HEPATOCELLULAR CARCINOMA","absent","NA","NA","NA","STA-9090","Hsp90","I","Advanced, Second line","Dose escalation/de-escalation study will be performed in order to determine the Phase 2 dose of STA-9090 given once weekly in patients with advanced hepatocellular carcinoma. The dose limiting toxicities will be determined at each dose level.","NCT01665937","NA","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT01665937","NA","135564985","ENSG00000104313","EFO_0009260","ABSENT NA NA","no biomarker"
"112",112,"ADVANCED OR LOCALLY METASTATIC HEPATOCELLULAR CARCINOMA","absent","NA","NA","NA","AXITINIB","NA","II","Advanced, Second line","Overall Survival (OS","NCT01210495","NA","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT01210495","DB06626","6450551","ENSG00000104313","EFO_0009260","ABSENT NA NA","no biomarker"
"113",113,"HEPATOCELLULAR CARCINOMA","absent","NA","NA","NA","188RE-SSS LIPIODOL","NA","I","Advanded, First line","Maximal tolerated dose","NCT01126463","no ressection/transplant","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT01126463","NA","NA","ENSG00000104313","EFO_0000182","ABSENT NA NA","failed drug,no biomarker"
"114",114,"ADVANCED HEPATOCELLULAR CARCINOMA","absent","NA","NA","NA","SORAFENIB, CS-1008","NA","II","Advanded, First line","time to progression (TTP) for chemotherapy naive subjects with advanced hepatocellular carcinoma (HCC)","NCT01033240","NA","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT01033240","DB00398,NA","406563, 3921152","ENSG00000104313","EFO_0009260","ABSENT NA NA","no biomarker"
"115",115,"ADVANCED HEPATOCELLULAR CARCINOMA","absent","NA","NA","NA","APATINIB","NA","II","Advanced, Second line","TTP (Time To Progression)","NCT01192971","NA","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT01192971","DB14765","45139106","ENSG00000104313","EFO_0009260","ABSENT NA NA","no biomarker"
"116",116,"HEPATOCELLULAR CARCINOMA","absent","NA","NA","NA","RAMUCIRUMAB DP","NA","III","Second line","Overall Survival (OS)","NCT01140347","NA","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT01140347","NA","NA","ENSG00000104313","EFO_0000182","ABSENT NA NA","failed drug,no biomarker"
"117",117,"ADVANCED OR PRIMARY HEPATOCELLULAR CARCINOMA","absent","NA","NA","NA","SODIUM BUTYRATE","NA","II","Advanded&non-advanced, First&Second line","Evaluating Tumor Response Rate","NCT01308645","(I believe sb (which is the only phrase listed in the trial) means sodium butyrate : https://www.ncbi.nlm.nih.gov/pubmed/9626359 )","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT01308645","NA","5222465","ENSG00000104313","EFO_0009260","ABSENT NA NA","no biomarker"
"118",118,"ADVANCED HEPATOCELLULAR CARCINOMA","absent","NA","NA","NA","SILYBIN","NA","I","Advanced, First&Second line","The maximum tolerated dose of siliphos in patients with advanced hepatocellular carcinoma ","NCT01129570","NA","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT01129570","NA","31553","ENSG00000104313","EFO_0009260","ABSENT NA NA","no biomarker"
"119",119,"ADVANCED HEPATOCELLULAR CARCINOMA","absent","NA","NA","NA","DOXORUBICIN, SORAFENIB","NA","II","Advanded, First line","Time to progression","NCT01272557","NA","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT01272557","DB00997,DB00398","443939, 406563","ENSG00000104313","EFO_0009260","ABSENT NA NA","no biomarker"
"120",120,"HEPATOCELLULAR CARCINOMA","absent","NA","NA","NA","DOXORUBICIN","NA","I/II","First line","Histopathological correlation with surgically resected tumor","NCT01116635","docorubicin is loaded into superabsorbent polymer microspheres, must be surgically resectable","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT01116635","DB00997","443939","ENSG00000104313","EFO_0000182","ABSENT NA NA","no biomarker"
"121",121,"HEPATOCELLULAR CARCINOMA","absent","NA","NA","NA","SORAFENIB","NA","IV","Advanced, First","Total (Cumulative) Dose Delivery of Sorafenib, Cumulative Dose of Sorafenib","NCT01203787","different dosing of Sorafenib, requires unresectable and/or metastatic","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT01203787","DB00398","406563","ENSG00000104313","EFO_0000182","ABSENT NA NA","no biomarker"
"122",122,"ADVANCED OR METASTAIC HEPATOCELLUAR CARCINOMA","absent","NA","NA","NA","BAY86-9766 MEK INHIBITOR, SORAFENIB","MEK, UNK","II","Advanced, First line","Disease Control Rate (DCR)","NCT01204177","NA","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT01204177","NA,DB00398","NA, 406563","ENSG00000104313","EFO_0009260","ABSENT NA NA","failed drug,no biomarker"
"123",123,"ADVANCED LIVER CANCER","absent","NA","NA","NA","EVEROLIMUS","NA","III","Advanced, Second line","Overall Survival (OS)","NCT01035229","advanced HCC whose disease progressed while on or after sorafenib treatment or who are intolerant to sorafenib.","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT01035229","DB01590","6442177","ENSG00000104313","MONDO_0002691","ABSENT NA NA","no biomarker"
"124",124,"UNRESECTABLE OR METASTATIC HEPATOCELLULAR CARCINOMA","absent","NA","NA","NA","TEMSIROLIMUS","mTOR","II","Advanced, Second line","Disease Progression","NCT01567930","must have received exactly one prior systemic therapy","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT01567930","DB06287","6918289","ENSG00000104313","EFO_0000702","ABSENT NA NA","no biomarker"
"125",125,"HEPATOCELLULAR CARCINOMA","absent","NA","NA","NA","SORAFENIB, PRAVASTATIN","NA","III","Advanced, First&Second line","determination of the tumor according to the evaluation criteria of Response Evaluation Criteria in Solid Tumors","NCT01903694","Palliative Treatment of Child-Pugh A Hepatocellular Carcinoma, does not specify the requirement to include?exclude prior treatment","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT01903694","DB00398,DB00175","406563, 16759173","ENSG00000104313","EFO_0000182","ABSENT NA NA","no biomarker"
"126",126,"HEPATOCELLULAR CARCINOMA","absent","NA","NA","NA","THALIDOMINE, TEGAFUR-URACIL","VEGF/bFGF, UNK","II","Second line","tumor recurrence","NCT02447679","to Decrease Hepatocellular Carcinoma Recurrence","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT02447679","NA,DB09327","5426, 104747","ENSG00000104313","EFO_0000182","ABSENT NA NA","no biomarker"
"127",127,"ADVANCED HEPATOCELLULAR CARCINOMA","absent","NA","NA","NA","SORAFENIB, CISPLATIN/FLUOROURACIL","NA","III","Advanced, First Line, Second line","Overall survival","NCT01214343","Does not state whether or not prior chemotherapy is needed or excluded","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT01214343","DB00398,NA","406563, NA","ENSG00000104313","EFO_0009260","ABSENT NA NA","no biomarker"
"128",128,"PRIMARY ADVANCED HEPATOCELLULAR CARCINOMA","absent","NA","NA","NA","SORAFENIB, ZOLEDRONIC ACID","NA","II","Advanced, First&Second line","numbers of adverse events","NCT01259193","only requirement for other treatment(s) ""Concomitant anti-cancer therapy (except immunotherapy and Chinese traditional treatment"". Must be unresectable","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT01259193","DB00398,DB00399","406563, 68740","ENSG00000104313","EFO_0009260","ABSENT NA NA","no biomarker"
"129",129,"HEPATOCELLULAR CARCINOMA","absent","NA","NA","NA","SORAFENIB","NA","II","First line","Progression Free Survival, Overall Survival","NCT01217034","must be done with Transcatheter Arterial Chemoembolization (TACE)","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT01217034","DB00398","406563","ENSG00000104313","EFO_0000182","ABSENT NA NA","no biomarker"
"130",130,"ADVANCED HEPATOCELLULAR CARCINOMA","absent","NA","NA","NA","SORAFENIB, VT-122","UNK, COX-2/beta-adrenergic receptor","II","Advanced, First line","failure free survival","NCT01265576","NA","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT01265576","DB00398,NA","406563, NA","ENSG00000104313","EFO_0009260","ABSENT NA NA","no biomarker"
"131",131,"ADVANCED HEPATOMA","absent","NA","NA","NA","CINOBUFACIN","NA","II","Advanced, First line, Second line","The evaluation of the patient's respondence for the therapy is carried out every phase, according to RECIST:CR,PR,SD and PD","NCT01236690","Combining the Arterial Embolotherapy, never states if prior treatment is an exclusion or a criteria","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT01236690","NA","NA","ENSG00000104313","EFO_0005856","ABSENT NA NA","failed drug,no biomarker"
"132",132,"ADVANCED HEPATOCELLULAR CARCINOMA","absent","NA","NA","NA","OXALIPLATIN, FLUOROURACIL/LEUCOVORIN","UNK, UNK","III","Advanced, First line","Overall survival","NCT03164382","done in the FOLFOX regimen","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03164382","DB00526,NA","5310940, NA","ENSG00000104313","EFO_0009260","ABSENT NA NA","no biomarker"
"133",133,"METASTATIC HEPATOCELLULAR CARCINOMA","absent","NA","NA","NA","SORAFENIB, HYDROXYCHLOROQUINE","UNK, UNK","II","Advanced, First&Second line","Time to tumor progression evaluated via tumor imaging","NCT03037437","experimental arms depending upon progression on sorafenib","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03037437","DB00398,DB01611","406563, 12947","ENSG00000104313","EFO_0000702","ABSENT NA NA","no biomarker"
"134",134,"HEPATOCELLULAR CARCINOMA","absent","NA","NA","NA","NIVOLUMAB","UNK","III","First line","Recurrence-free Survival (RFS)","NCT03383458","needs to have had curative resection or ablation","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03383458","DB09035","NA","ENSG00000104313","EFO_0000182","ABSENT NA NA","no biomarker"
"135",135,"HEPATOCELLULAR CARCINOMA","absent","NA","NA","NA","MECLIZINE","androstane receptor","I","First line","Change in mRNA levels","NCT03253289","Patients must be candidate for surgical resection, ablation, and TACE.","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03253289","DB00737","64713","ENSG00000104313","EFO_0000182","ABSENT NA NA","no biomarker"
"136",136,"ADVANCED HEPATOCELLULAR CARCINOMA","absent","NA","NA","NA","DURVALUMAB, TREMELIMUMAB","UNK, UNK","III","Advanced, First line","Overall Survival (OS)","NCT03298451","had different experimental arms with varying drugs","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03298451","DB11714,DB11771","NA, NA","ENSG00000104313","EFO_0009260","ABSENT NA NA","no biomarker"
"137",137,"METASTATIC HEPATOCELLULAR CARCINOMA","absent","NA","NA","NA","MILCICLIB MALEATE","UNK","II","Advanced, Second line","Overall Safety Profile","NCT03109886","second line, as long as no other experimental/immunotherapy agents have been used","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03109886","NA","46937352","ENSG00000104313","EFO_0000702","ABSENT NA NA","no biomarker"
"138",138,"PRIMARY HEPATOCELLUAR CARCINOMA","absent","NA","NA","NA","S-ADENOSYL METHIONINE","UNK","UNK","First line","Time to tumor recurrence","NCT03178929","NA","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03178929","NA","34756","ENSG00000104313","EFO_0000182","ABSENT NA NA","no biomarker"
"139",139,"LIVER CANCER","absent","NA","NA","NA","NIVOLUMAB","UNK","I","First line","Number of participants with treatment-related adverse events as assessed by CTCAE v4.0","NCT03143270","must be done with Drug Eluting Bead Transarterial Chemoembolization","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03143270","DB09035","NA","ENSG00000104313","MONDO_0002691","ABSENT NA NA","no biomarker"
"140",140,"HEPATOCELLULAR CARCINOMA","absent","NA","NA","NA","CELEBREX, METFORMIN","UNK, UNK","III","First line","Number of participants with tumor recurrence","NCT03184493","NA","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03184493","NA,DB00331","2662, 14219","ENSG00000104313","EFO_0000182","ABSENT NA NA","no biomarker"
"141",141,"ADVANCED HEPATOCELLULAR CARCINOMA","absent","NA","NA","NA","LENVATINIB, PEMBROLIZUMAB","UNK, UNK","I","Advanced, Second line","Number of participants with any serious adverse event and number of participants with any non-serious adverse event., Dose-limiting toxicity (DLT) of lenvatinib and pembrolizumab during Cycle 1, Expansion part: Objective response rate (ORR) by mRECIST and RECIST 1.1 based on IIR analysis , Expansion part: Duration of response (DOR) by mRECIST and RECIST 1.1 based on IIR analysis","NCT03006926","NA","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03006926","DB09078,DB09037","11237762, NA","ENSG00000104313","EFO_0009260","ABSENT NA NA","no biomarker"
"142",142,"HEPATOCELLULAR CARCINOMA","absent","NA","NA","NA","ATORVASTATIN","UNK","IV","First line","3-year cumulative incidence of recurrent HCC between the intervention group and control counterpart","NCT03024684","after recetion/ablation","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03024684","DB01076","60822","ENSG00000104313","EFO_0000182","ABSENT NA NA","no biomarker"
"143",143,"HEPATOCELLULAR CARCINOMA","absent","NA","NA","NA","NIVOLUMAB, IPILIMUMAB","UNK, UNK","I","First &Second line","Number of participants with adverse events","NCT03203304","must include radiotherapy, states prior therapy is allowed but not required","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03203304","DB09035,DB06186","NA, NA","ENSG00000104313","EFO_0000182","ABSENT NA NA","no biomarker"
"144",144,"LIVER CANCER","absent","NA","NA","NA","CPG DNA","UNK","I","First line","survival time, metastasis free survival time","NCT03235167","Must be done with TACE therapy","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03235167","NA","NA","ENSG00000104313","MONDO_0002691","ABSENT NA NA","failed drug,no biomarker"
"145",145,"ADVANCED HEPATOCELLULAR CARCINOMA","absent","NA","NA","NA","PD-1 IMMUNE CHECK INHIBITOR","PD1","II","Advanced, First&Second line","Response rate","NCT03259867","PD1 checkpoint inhibitor (either nivolumab or pembrolizumab). Done with TACE","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03259867","NA","NA","ENSG00000104313","EFO_0009260","ABSENT NA NA","failed drug,no biomarker"
"146",146,"ADVANCED HEPATOCELLULAR CARCINOMA","absent","NA","NA","NA","CAPECITABINE, APATINIB","UNK, UNK","II","Advanced, Second line","time to progression","NCT03114085","NA","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03114085","DB01101,DB14765","60953, 45139106","ENSG00000104313","EFO_0009260","ABSENT NA NA","no biomarker"
"147",147,"ADVANCED HEPATOCELLULAR CARCINOMA","absent","NA","NA","NA","SF1126, NIVOLUMAB","PI3K/BRD4, PD1","I","Advanced, Second line","Rate of dose limiting toxicities ","NCT03059147","NA","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03059147","DB05210,DB09035","66577114, NA","ENSG00000104313","EFO_0009260","ABSENT NA NA","no biomarker"
"148",148,"ADVANCED HEPATOCELLULAR CARCINOMA","absent","NA","NA","NA","ICARITIN","ERa36","III","Advanced, First line","Overall survival (OS)","NCT03236636","NA","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03236636","DB12672","5318980","ENSG00000104313","EFO_0009260","ABSENT NA NA","no biomarker"
"149",149,"BILE DUCT CARCINOMA","absent","NA","NA","NA","SHR-1210, APATINIB","UNK, UNK","II","Advanced, First line","The safety and tolerability","NCT03092895","Treated with the FOLFOX4 and GEMOX regimen concurently","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03092895","NA,DB14765","NA, 45139106","ENSG00000104313","EFO_0005540","ABSENT NA NA","failed drug,no biomarker"
"150",150,"ADVANCED HEPATOCELLULAR CARCINOMA","absent","NA","NA","NA","GALUNISERTIB","UNK","I","Advanced, Second line","Safety based upon standard laboratory and clinical adverse event monitoring","NCT02906397","must be combined with SBRT","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT02906397","DB11911","10090485","ENSG00000104313","EFO_0009260","ABSENT NA NA","no biomarker"
"151",151,"METASTATIC HEPATOCELLULAR CARCINOMA","absent","NA","NA","NA","ASLAN001","EGFR/HER2/HER4","I","Advanced, Second line","Definition of MTD (maximum tolerable dose)","NCT03499626","had two different phase cohorts","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03499626","NA","42642648","ENSG00000104313","EFO_0000702","ABSENT NA NA","no biomarker"
"152",152,"METASTATIC HEPATOCELLULAR CARCINOMA","HER3","Positive","NA","Protein Expression","ASLAN001","EGFR/HER2/HER4","I","Advanced, Second line","Definition of MTD (maximum tolerable dose)","NCT03499626","had two different phase cohorts","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03499626","NA","42642648","ENSG00000065361","EFO_0000702","HER3 PROTEIN EXPRESSION POSITIVE","pass"
"153",153,"HEPATOCELLULAR CARCINOMA","absent","NA","NA","NA","NIVOLUMAB","PD1","II","First line","Rate and type of adverse events, liver decompensation, and transient and permanent drug discontinuations due to toxicity","NCT03380130","Must be done with SIRT","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03380130","DB09035","NA","ENSG00000104313","EFO_0000182","ABSENT NA NA","no biomarker"
"154",154,"ADVANCED HEPATOCELLULAR CARCINOMA","absent","NA","NA","NA","AVELUMAB","UNK","II","Advanced, Second line","response rate ","NCT03389126","sorafeib had to fail, or pt was intolerant","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03389126","DB11945","NA","ENSG00000104313","EFO_0009260","ABSENT NA NA","no biomarker"
"155",155,"ADVANCED HEPATOCELLULAR CARCINOMA","absent","NA","NA","NA","PEMBROLIZUMAB","UNK","III","Advanced, Second line","Overall Survival (OS)","NCT03062358","NA","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03062358","DB09037","NA","ENSG00000104313","EFO_0009260","ABSENT NA NA","no biomarker"
"156",156,"ADVANCED HEPATOCELLULAR CARCINOMA","absent","NA","NA","NA","PDR001, SORAFENIB","UNK, UNK","I","Advanced, First line","Number of participants with Adverse Events (AEs) as a measure of safety and tolerability","NCT02988440","NA","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT02988440","NA,DB00398","NA, 406563","ENSG00000104313","EFO_0009260","ABSENT NA NA","failed drug,no biomarker"
"157",157,"HEPATOCELLULAR CARCINOMA","absent","NA","NA","NA","BTG-002814","UNK","I","First line","Adverse events (AEs) related to treatment with BTG-002814 using the National Cancer Institute- Common Terminology Criteria for Adverse Events- Version 4.0 (NCI-CTCAE v4.0), Adverse events (AEs) related to treatment with BTG-002814 using the National Cancer Institute- Common Terminology Criteria for Adverse Events- Version 4.0 (NCI-CTCAE v4.0), Concentration of vandetanib and N-desmethyl vandetanib in resected liver tissue following treatment with BTG-002814","NCT03291379","must be resectable","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03291379","NA","NA","ENSG00000104313","EFO_0000182","ABSENT NA NA","failed drug,no biomarker"
"158",158,"UNRESECTABLE HEPATOCELLULAR CARCINOMA","absent","NA","NA","NA","BGB-A317","PD1","III","First line","Overall Survival (OS)","NCT03412773","had primary objectives for substudies that were excluded","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03412773","NA","NA","ENSG00000104313","EFO_0000707","ABSENT NA NA","failed drug,no biomarker"
"159",159,"ADVANCED HEPATOCELLULAR CARCINOMA","absent","NA","NA","NA","PEMBROLIZUMAB","UNK","II","Advanced, Second line","Overall response rate","NCT03163992","NA","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03163992","DB09037","NA","ENSG00000104313","EFO_0009260","ABSENT NA NA","no biomarker"
"160",160,"HEPATOCELLULAR CARCINOMA","absent","NA","NA","NA","PEMBROLIZUMAB","UNK","II","First line","One-year recurrence-free survival rate","NCT03337841","Hepatocellular carcinoma for which radical cure is possible by resection or RFA.","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03337841","DB09037","NA","ENSG00000104313","EFO_0000182","ABSENT NA NA","no biomarker"
"161",161,"ADVANCED HEPATOCELLULAR CARCINOMA","absent","NA","NA","NA","BRIVANIB","UNK","II","Advanced, Second line","Disease control rate (DCR), Time to Progress (TTP)","NCT03516071","NA","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03516071","DB11958","11234052","ENSG00000104313","EFO_0009260","ABSENT NA NA","no biomarker"
"162",162,"RESECTABLE LIVER CANCER","absent","NA","NA","NA","IPILIMUMAB, NIVOLUMAB","CTLA4, UNK","II","First &Second line","Incidence of adverse events","NCT03222076","Patient can have had prior treatment for HCC including prior surgery, radiation therapy, local-regional therapy (ablation or arterial directed therapies), and systemic therapy including sorafenib or chemotherapy (but not anti-PD-1 or anti-CTLA-4 therapy)","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03222076","DB06186,DB09035","NA, NA","ENSG00000104313","MONDO_0002691","ABSENT NA NA","no biomarker"
"163",163,"INTERMEDIATE STAGE HEPATOCELLULAR CARCINOMA","absent","NA","NA","NA","TIRAPAZAMINE","UNK","II","First line","Progression Free Survival ","NCT03145558","TATE vs TACE","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03145558","DB04858","135413511","ENSG00000104313","EFO_0000707","ABSENT NA NA","no biomarker"
"164",164,"ADVANCED HEPATOCELLULAR CARCINOMA","absent","NA","NA","NA","KN035","UNK","I","Advanced, Second line","Incidence of dose limiting toxicities (DLTs) in dose escalation study, Percentage of participants with adverse events (AEs), serious adverse events and AEs of special interest, ORR of HCC patients in dose expansion study","NCT03101488","included other cancers, but specifcally seperated HCC","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03101488","NA","NA","ENSG00000104313","EFO_0009260","ABSENT NA NA","failed drug,no biomarker"
"165",165,"HEPATOCELLULAR CARCINOMA","absent","NA","NA","NA","APATINIB","VEGFR2","II","First line","Recurrence-free survival","NCT03261791","must have underwent resection, and have a PVTT","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03261791","DB14765","45139106","ENSG00000104313","EFO_0000182","ABSENT NA NA","no biomarker"
"166",166,"ADVANCED HEPATOCELLULAR CARCINOMA","absent","NA","NA","NA","ATORVASTATIN","UNK","II","Advanced, First line","Overall survival","NCT03275376","taken with standard therapy sorafenib","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03275376","DB01076","60822","ENSG00000104313","EFO_0009260","ABSENT NA NA","no biomarker"
"167",167,"HEPATOCELLULAR CARCINOMA","absent","NA","NA","NA","CISPLATIN, DOXORUBICIN","UNK, UNK","III","First line","Event-free survival (EFS), Response in HCC is defined as complete (CR) or partial (PR) response according to RECIST version 1.1 criteria","NCT03017326","separates cohorts resected (experimental) and unresected (comparator)","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03017326","DB00515,DB00997","2767, 443939","ENSG00000104313","EFO_0000182","ABSENT NA NA","no biomarker"
"168",168,"HEPATOBLASTOMA","absent","NA","NA","NA","CISPLATIN","UNK","III","First line","Event-free survival (EFS)","NCT03017326","separates cohorts by very low risk (experimental) and low/intermediate risk","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03017326","DB00515","2767","ENSG00000104313","EFO_1000292","ABSENT NA NA","no biomarker"
"169",169,"HEPATOCELLULAR CARCINOMA","absent","NA","NA","NA","NEO-MASCT","UNK","II","First line","Disease free survival, Immune response rate","NCT03067493","combined with RFA","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03067493","NA","NA","ENSG00000104313","EFO_0000182","ABSENT NA NA","failed drug,no biomarker"
"170",170,"ADVANCED HEPATOCELLULAR CARCINOMA","PD1","Positive","NA","Protein Expression","APL-501","PD1","I","Advanced, Second line","Number of participants with treatment related adverse events as assessed by Common Terminology Criteria for Adverse Events (CTCAE v4.03) in patients with advance solid tumors","NCT03053466","included other cancers, but specifcally seperated HCC with a biomarker","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03053466","NA","NA","ENSG00000145335","EFO_0009260","PD1 PROTEIN EXPRESSION POSITIVE","failed drug"
"171",171,"BILIARY TRACT CARCINOMA","absent","NA","NA","NA","PEMBROLIZUMAB, OXALIPLATIN","PD1, UNK, UNK","II","Advanced, Second line","5-month PFS","NCT03111732","NA","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03111732","DB09037,DB00526","NA, 5310940","ENSG00000104313","MONDO_0018531","ABSENT NA NA","no biomarker"
"172",172,"METASTATIC HEPATOCELLULAR CARCINOMA","absent","NA","NA","NA","ATEZOLIZUMAB, CABOZANTINIB","UNK, UNK","I/II","Advanced, First line","objective response rate [ORR], safety of the recommended combination dose of cabozantinib with atezolizumab","NCT03170960","Had other cancers, but HCC was in its own cohort","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03170960","DB11595,DB08875","NA, 25102846","ENSG00000104313","EFO_0000702","ABSENT NA NA","no biomarker"
"173",173,"METASTATIC HEPATOCELLULAR CARCINOMA","absent","NA","NA","NA","TREMELIMUMAB, DURVALUMAB","UNK, UNK","II","Advanced, Second line","Best Overall Response rate","NCT03482102","must be done with radiation","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03482102","DB11771,DB11714","NA, NA","ENSG00000104313","EFO_0000702","ABSENT NA NA","no biomarker"
"174",174,"METASTATIC BILIARY TRACT CANCER","absent","NA","NA","NA","TREMELIMUMAB, DURVALUMAB","UNK, UNK","II","Advanced, Second line","Best Overall Response rate","NCT03482102","must be done with radiation","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03482102","DB11771,DB11714","NA, NA","ENSG00000104313","MONDO_0003060","ABSENT NA NA","no biomarker"
"175",175,"HEPATOCELLULAR CARCINOMA","absent","NA","NA","NA","BABAODAN","UNK","IV","First line","3-year disease free survival","NCT03515369","must be done with curative resection","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03515369","NA","NA","ENSG00000104313","EFO_0000182","ABSENT NA NA","failed drug,no biomarker"
"176",176,"HEPATOCELLULAR CARCINOMA","absent","NA","NA","NA","APATINIB","VEGFR","II","First line","overall survival","NCT03520257","must be With BCLC-C Stage I and Stage II Portal Vein Tumor Thrombus. Must be done with radiotherapy","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03520257","DB14765","45139106","ENSG00000104313","EFO_0000182","ABSENT NA NA","no biomarker"
"177",177,"ADVANCED HEPATOCELLULAR CARCINOMA","absent","NA","NA","NA","SORAFENIB, CVM-1118","VEGF, UNK","II","Advanced, First line","Objective Response Rate (ORR)","NCT03582618","NA","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03582618","DB00398,NA","406563, 49840582","ENSG00000104313","EFO_0009260","ABSENT NA NA","no biomarker"
"178",178,"ADVANCED LIVER CANCER","WNT/β-catenin","Positive","NA","Protein Expression","DKN-01, SORAFENIB","UNK, UNK","I/II","Advanced, First line","Phase I: Adverse Events , Phase II: Time to progression (TTP2)","NCT03645980","NA","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03645980","NA,DB00398","NA, 406563","NA","MONDO_0002691","WNT/Β-CATENIN PROTEIN EXPRESSION POSITIVE","failed drug,failed biomarker"
"179",179,"INTERMEDIATE STAGE HEPATOCELLULAR CARCINOMA","absent","NA","NA","NA","NIVOLUMAB","UNK","II","First line","Objective Response Rate (ORR)","NCT03572582","Must be done with TACE","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03572582","DB09035","NA","ENSG00000104313","EFO_0000707","ABSENT NA NA","no biomarker"
"180",180,"ADVANCED LIVER CANCER","absent","NA","NA","NA","ANLOTINIB","UNK","UNK","Advanced, First line","Progression free survival","NCT03766776","NA","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03766776","DB11885","57380530","ENSG00000104313","MONDO_0002691","ABSENT NA NA","no biomarker"
"181",181,"LOCOREGIONAL HEPATOCELLULAR CARCINOMA","absent","NA","NA","NA","DURVALUMAB, BEVACIZUMAB","UNK, UNK","III","First line","Progression Free Survival (PFS) for Arm A vs Arm C","NCT03778957","must be done with tace","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03778957","DB11714,DB00112","NA, NA","ENSG00000104313","EFO_0000707","ABSENT NA NA","no biomarker"
"182",182,"HEPATOCELLULAR CARCINOMA","absent","NA","NA","NA","APATINIB","UNK","II","Second line","Time To Progression","NCT03510416","Must be done with TACE","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03510416","DB14765","45139106","ENSG00000104313","EFO_0000182","ABSENT NA NA","no biomarker"
"183",183,"ADVANCED HEPATOCELLULAR CARCINOMA","absent","NA","NA","NA","SINTILIMAB, IBI305","UNK, UNK","I","Advanced, Second line","Incicende of Adverse Events (AEs)","NCT04072679","NA","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT04072679","NA,NA","NA, NA","ENSG00000104313","EFO_0009260","ABSENT NA NA","failed drug,no biomarker"
"184",184,"UNRESECTABLE HEPATOCELLULAR CARCINOMA","absent","NA","NA","NA","DEFEROXAMINE","UNK","I","First line","Progression Free Survival (PFS) in Participants With Unresectable Hepatocellular Cance","NCT03652467","combined with TACE","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03652467","DB00746","62881","ENSG00000104313","EFO_0000707","ABSENT NA NA","no biomarker"
"185",185,"RESECTABLE HEPATOCELLULAR CARCINOMA","absent","NA","NA","NA","OXALIPLATIN, FLUOROURACIL, LEUCOVORIN","UNK, UNK, UNK","III","First line","Overall survival ","NCT03469479","Also call FOLFOX","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03469479","DB00526,DB00544,DB00650","5310940, 3385, 135403647","ENSG00000104313","EFO_0000707","ABSENT NA NA","no biomarker"
"186",186,"ADVANCED HEPATOCELLULAR CARCINOMA","absent","NA","NA","NA","LENVATINIB","UNK","III","Advanced, First line","overall survival, progression-free survival","NCT04053985","combined with TAI","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT04053985","DB09078","11237762","ENSG00000104313","EFO_0009260","ABSENT NA NA","no biomarker"
"187",187,"LOCALLY ADVANCED HEPATOCELLULAR CARCINOMA","absent","NA","NA","NA","CABOZANTINIB, NIVOLUMAB","UNK, UNK","I","Advanced, First &Second line","Number of adverse events in participants of neoadjuvant cabozantinib plus nivolumab, Number of patients who complete pre-op treatment and proceed to surgery","NCT03299946","prior therapy had to have been over 6 months in advance","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03299946","DB08875,DB09035","25102846, NA","ENSG00000104313","EFO_0009260","ABSENT NA NA","no biomarker"
"188",188,"ADVANCED HEPATOCELLULAR CARCINOMA","absent","NA","NA","NA","PEMBROLIZUMAB, BAVITUXIMAB","UNK, UNK","II","Advanced, First line","Overall Response Rate ","NCT03519997","NA","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03519997","DB09037,DB05136","NA, NA","ENSG00000104313","EFO_0009260","ABSENT NA NA","no biomarker"
"189",189,"HEPATOCELLULAR CARCINOMA","absent","NA","NA","NA","ANLOTINIB, AK105","TKI, PD1","II","First line","Objective response rate (ORR)","NCT04172571","NA","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT04172571","DB11885,NA","57380530, NA","ENSG00000104313","EFO_0000182","ABSENT NA NA","no biomarker"
"190",190,"ADVANCED HEPATOCELLULAR CARCINOMA","absent","NA","NA","NA","CHIAURANIB","VEGFR2/VEGFR1/VEGFR3/PDGFRa/c-Kit/mitosis-related kinase Aurora B/CSF-1R","I","Advanced, First &Second line","16 weeks progression-free rate (16W-PFR)","NCT03245190","cannot have therapy two weeks before start of trial","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03245190","NA","49779393","ENSG00000104313","EFO_0009260","ABSENT NA NA","no biomarker"
"191",191,"HEPATOCELLULAR CARCINOMA","AFP","neagative","NA","Protein Expression","APATINIB, SHR-1210","VEGFR2, PD1","UNK","First line","relapse-free survival(RFS),Overall survival(OS)","NCT03722875","NA","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03722875","DB14765,NA","45139106, NA","ENSG00000081051","EFO_0000182","AFP PROTEIN EXPRESSION NEAGATIVE","pass"
"192",192,"HEPATOCELLULAR CARCINOMA","absent","NA","NA","NA","IDARUBICIN","UNK","II","First line","Rate of patients in objective response (complete or partial response)","NCT02185768","done with Chemoembolization","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT02185768","DB01177","636362","ENSG00000104313","EFO_0000182","ABSENT NA NA","no biomarker"
"193",193,"ADVANCED HEPATOCELLULAR CARCINOMA","absent","NA","NA","NA","BBI503, SORAFENIB","UNK, UNK","I","Advanced, First&Second line","Determine of the Maximum Tolerated Dose (MTD) of BBI503 monotherapy and in combination with Sorafenib by assessing dose-limiting toxicities (DLTs) , Number of Participants with Adverse Events as a Measure of Safety and Tolerability, Pharmacokinetic profile of BBI503","NCT02354898","Only requirement is no chemo for 4 weeks before start, no prior treatment with BBi503","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT02354898","NA,DB00398","25190990, 406563","ENSG00000104313","EFO_0009260","ABSENT NA NA","no biomarker"
"194",194,"ADVANCED HEPATOCELLULAR CARCINOMA","absent","NA","NA","NA","OXALIPLATIN, FLUOROURACIL","UNK, UNK","IV","Advanced, First line","Progression-free survival (PFS)","NCT02557503","used in HAIC after TACE","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT02557503","DB00526,DB00544","5310940, 3385","ENSG00000104313","EFO_0009260","ABSENT NA NA","no biomarker"
"195",195,"HEPATOCELLULAR CARCINOMA","AFP","positive","NA","Protein expression","RAMUCIRUMAB","UNK","III","Second line","Overall Survival (OS)","NCT02435433","NA","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT02435433","DB05578","NA","ENSG00000081051","EFO_0000182","AFP PROTEIN EXPRESSION POSITIVE","pass"
"196",196,"RECURRENT HEPATOCELLULAR CARCINOMA","AFP","positive","NA","Protein expression","GALUNISERTIB, NIVOLUMAB","Growth Factor-beta Receptor I Kinase, PD1","I/II","Advanced, Second line","Phase 1b: Maximum Tolerated Dose of Galunisertib in Combination with Nivolumab","NCT02423343","NA","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT02423343","DB11911,DB09035","10090485, NA","ENSG00000081051","EFO_0000707","AFP PROTEIN EXPRESSION POSITIVE","pass"
"197",197,"HEPATOCELLULAR CARCINOMA","absent","NA","NA","NA","S-ADENOSYL METHIONINE","UNK","I","First line","Time to tumor recurrence","NCT02586285","done with curative resection. To prevent reccurence","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT02586285","NA","34756","ENSG00000104313","EFO_0000182","ABSENT NA NA","no biomarker"
"198",198,"ADVANCED HEPATOCELLULAR CARCINOMA","absent","NA","NA","NA","APATINIB","UNK","I/II","Advanced, Second line","Progression free survival","NCT02727309","could have refused first line treatment","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT02727309","DB14765","45139106","ENSG00000104313","EFO_0009260","ABSENT NA NA","no biomarker"
"199",199,"HEPATOCELLULAR CARCINOMA","FGF19","positive/negative","NA","protein expression","FISOGATINIB","UNK","I","Second line","Maximum tolerated dose (MTD) on qd and bid schedules , Recommended Phase 2 dose of fisogatinib (BLU-554) on qd and bid schedules, Number of patients with adverse events, serious adverse events and changes in physical findings, vital signs, clinical laboratory results and ECG findings","NCT02508467","both positive and negative FGF19 pts could join trial, but they wouldn’t reviece the same amount of the drug","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT02508467","NA","91885617","ENSG00000162344","EFO_0000182","FGF19 PROTEIN EXPRESSION POSITIVE/NEGATIVE","pass"
"200",200,"ADVANCED HEPATOCELLULAR CARCINOMA","absent","NA","NA","NA","DURVALUMAB, TREMELIMUMAB, BEVACIZUMAB","UNK, UNK, UNK","II","Advanced, First&Second line","Number of subjects reporting adverse events and number of subjects reporting serious adverse events, Number of subjects experiencing dose limiting toxicities","NCT02519348","one group could not have any prior treatment (systemic) for HCC","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT02519348","DB11714,DB11771,DB00112","NA, NA, NA","ENSG00000104313","EFO_0009260","ABSENT NA NA","no biomarker"
"201",201,"ADVANCED HEPATOCELLULAR CARCINOMA","absent","NA","NA","NA","ENZALUTAMIDE","UNK","II","Advanced, Second line","Overall Survival (OS)","NCT02528643","NA","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT02528643","DB08899","15951529","ENSG00000104313","EFO_0009260","ABSENT NA NA","no biomarker"
"202",202,"ADVANCED HEPATOCELLULAR CARCINOMA","Adrogen Receptors","positive/negative","NA","protein expression","ENZALUTAMIDE, SORAFENIB","androgen receptors, UNK","I/II","Advanced, First line","Progression-free survival","NCT02642913","NA","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT02642913","DB08899,DB00398","15951529, 406563","NA","EFO_0009260","ADROGEN RECEPTORS PROTEIN EXPRESSION POSITIVE/NEGATIVE","failed biomarker"
"203",203,"INTERMEDIATE STAGE HEPATOCELLULAR CARCINOMA","absent","NA","NA","NA","SORAFENIB","UNK","UNK","First line","Overall survival ","NCT02529761","testing sorafenib combined with TACE","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT02529761","DB00398","406563","ENSG00000104313","EFO_0000707","ABSENT NA NA","no biomarker"
"204",204,"ADVANCED HEPATOCELLULAR CARCINOMA","absent","NA","NA","NA","BBI608, SORAFENIB","UNK, UNK","I","Advanced, First line","Assessment of safety and tolerability of BBI608 given in combination with Sorafenib by reporting of adverse events and serious adverse events, Assessment of dose-limiting toxicities (DLTs), Pharmacokinetic profile of BBI608 when administered in combination with Sorafenib","NCT02358395","NA","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT02358395","NA,DB00398","10331844, 406563","ENSG00000104313","EFO_0009260","ABSENT NA NA","no biomarker"
"205",205,"HEPATOCELLULAR CARCINOMA","absent","NA","NA","NA","SORAFENIB","UNK","IV","First line","Complete remission","NCT02504983","some arms had sorafenib combined with tace. Trial focused on the GALNT14 genotype, however, never included testing for that genotype in the criteria","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT02504983","DB00398","406563","ENSG00000104313","EFO_0000182","ABSENT NA NA","no biomarker"
"206",206,"ADVANCED HEPATOCELLULAR CARCINOMA","absent","NA","NA","NA","NIVOLUMAB","UNK","III","Advanced, First line","Overall Survival (OS)","NCT02576509","NA","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT02576509","DB09035","NA","ENSG00000104313","EFO_0009260","ABSENT NA NA","no biomarker"
"207",207,"ADVANCED HEPATOCELLULAR CARCINOMA","FGF19","positive","NA","Protein expression&amplification","ERDAFITINIB","UNK","I/II","Advanced, Second line","Part 1:Recommended Phase 2 Dose (RP2D), Number of participants with Objective Response","NCT02421185","NA","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT02421185","DB12147","67462786","ENSG00000162344","EFO_0009260","FGF19 PROTEIN EXPRESSION&AMPLIFICATION POSITIVE","pass"
"208",208,"EARLY STAGE HEPATOCELLULAR CARCINOMA","AFP","positve/negative","NA","Protein expression","OXALIPLATIN, 5-FLUOROURACIL","UNK, UNK","II/III","First line","Recurrence Free Survival","NCT02767375","AFP < 400","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT02767375","DB00526,DB00544","5310940, 3385","ENSG00000081051","EFO_0001663","AFP PROTEIN EXPRESSION POSITVE/NEGATIVE","pass"
"209",209,"NEWLY DIAGNOSED ADVANCED HEPATOCELLULAR CARCINOMA","absent","NA","NA","NA","DEXANABINOL, SORAFENIB","UNK, UNK","I","Advanced, First line","Maximum Tolerated Dose (MTD) of dexanabinol given in combination with standard chemotherapies, Number of adverse events (AEs) in patients receiving dexanabinol monotherapy, Number of adverse events (AEs) in patients receiving dexanabinol in combination with standard chemotherapies","NCT02423239","Also included other cancer, but HCC was in its own cohor","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT02423239","DB06444,DB00398","107778, 406563","ENSG00000104313","EFO_0009260","ABSENT NA NA","no biomarker"
"210",210,"ADVANCED HEPATOCELLULAR CARCINOMA","absent","NA","NA","NA","SORAFENIB, METFORMIN","UNK, UNK","II","Advanced, First line","Overall Survival","NCT02672488","NA","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT02672488","DB00398,DB00331","406563, 14219","ENSG00000104313","EFO_0009260","ABSENT NA NA","no biomarker"
"211",211,"ADVANCED HEPATOCELLULAR CARCINOMA","absent","NA","NA","NA","AXITINIB","angiogenisis","I","Advanced, Second line","The maximal tolerated dose (MTD)","NCT02814461","must be done with radiation.","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT02814461","DB06626","6450551","ENSG00000104313","EFO_0009260","ABSENT NA NA","no biomarker"
"212",212,"ADVANCED FIBROLAMELLAR CARCINOMA","absent","NA","NA","NA","ENMD-2076","UNK","II","Advanced, First&Second line","Overall Response Rate","NCT02234986","NA","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT02234986","NA","16041424","ENSG00000104313","EFO_0009260","ABSENT NA NA","no biomarker"
"213",213,"ADVANCED HEPATOBILIARY CANCER","absent","NA","NA","NA","BBI503","UNK","II","Advanced, Second line","Disease Control Rate (DCR)","NCT02232633","NA","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT02232633","NA","25190990","ENSG00000104313","EFO_0000311","ABSENT NA NA","no biomarker"
"214",214,"ADVANCED HEPATOCELLULAR CANCER","absent","NA","NA","NA","BBI503","UNK","II","Advanced, Second line","Disease Control Rate (DCR)","NCT02232633","NA","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT02232633","NA","25190990","ENSG00000104313","EFO_0000311","ABSENT NA NA","no biomarker"
"215",215,"CHOLANGIOCARCINOMA","absent","NA","NA","NA","BBI503","UNK","II","Advanced, Second line","Disease Control Rate (DCR)","NCT02232633","NA","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT02232633","NA","25190990","ENSG00000104313","EFO_0005221","ABSENT NA NA","no biomarker"
"216",216,"HEPATOCELLULAR CARCINOMA","absent","NA","NA","NA","SORAFENIB","UNK","UNK","First line","recurrence-free survival","NCT02537158","treating MVI, sorafenib was being tested vs TACE, must be done after a resection","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT02537158","DB00398","406563","ENSG00000104313","EFO_0000182","ABSENT NA NA","no biomarker"
"217",217,"ADVANCED HEPATOCELLULAR CARCINOMA","absent","NA","NA","NA","CELECOXIB, SORAFENIB","UNK, UNK","IV","Advanced, Second line","Incidence of participants with clinically definite Sorafenib-related Hand Foot Syndrome, SECONDAY OUTCOME MEASURE: Overall survival","NCT02961998","Treating HFS. However, also testing synergistic effect on HCC","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT02961998","DB00482,DB00398","2662, 406563","ENSG00000104313","EFO_0009260","ABSENT NA NA","no biomarker"
"218",218,"CHOLANGIOCARCINOMA","absent","NA","NA","NA","DKN-01, GEMCITABINE, CISPLATIN","UNK, UNK, UNK","I","Second line","Maximum tolerated dose and dose-limiting toxicities as determined in Part A, Composite Safety parameters as assessed by new or changing physical examinations, vital signs, electrocardiograms (ECGs), clinical laboratories, concomitant medication reviews, and assessment of adverse events","NCT02375880","NA","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT02375880","NA,DB00441,DB00515","NA, 60750, 2767","ENSG00000104313","EFO_0005221","ABSENT NA NA","failed drug,no biomarker"
"219",219,"BILE DUCT CANCER","absent","NA","NA","NA","DKN-01, GEMCITABINE, CISPLATIN","UNK, UNK, UNK","I","First&Second line","Maximum tolerated dose and dose-limiting toxicities as determined in Part A, Composite Safety parameters as assessed by new or changing physical examinations, vital signs, electrocardiograms (ECGs), clinical laboratories, concomitant medication reviews, and assessment of adverse events","NCT02375880","NA","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT02375880","NA,DB00441,DB00515","NA, 60750, 2767","ENSG00000104313","MONDO_0003059","ABSENT NA NA","failed drug,no biomarker"
"220",220,"ADVANCED HEPATOCELLULAR CARCINOMA","MET","Positive","NA","Protein expression/protein expression&amplification/mutation","METATINIB TROMETHAMINE","UNK","I","Advanced, Second line","incidence of adverse events","NCT02650375","NA","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT02650375","NA","NA","ENSG00000105976","EFO_0009260","MET PROTEIN EXPRESSION/PROTEIN EXPRESSION&AMPLIFICATION/MUTATION POSITIVE","failed drug"
"221",221,"ADVANCED HEPATOCELLULAR CARCINOMA","absent","NA","NA","NA","MOGAMULIZUMAB, NIVOLUMAB","CCR4, PD1","I/II","Advanced, Second line","Maximum Tolerated Dose (MTD), Number of subjects experiencing dose-limiting toxicity","NCT02705105","included other cancers, but had a list of criteria for HCC","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT02705105","DB12498,DB09035","NA, NA","ENSG00000104313","EFO_0009260","ABSENT NA NA","no biomarker"
"222",222,"ADVANCED HEPATOCELLULAR CARCINOMA","absent","NA","NA","NA","APATINIB, SHR-1210","VEGFR, PD1","I/II","Advanced, Second line","Overall survival rate","NCT02942329","included gastric cancer as well, but laid out hcc criteria","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT02942329","DB14765,NA","45139106, NA","ENSG00000104313","EFO_0009260","ABSENT NA NA","no biomarker"
"223",223,"METASTATIC HEPATOCELLULAR CARCINOMA","absent","NA","NA","NA","MLN0128","UNK","I/II","Advanced, First&Second line","Phase I: Maximum Tolerated Dose (MTD) of MLN0128 , Phase II: Time to Progression (TTP)","NCT02575339","Phase one subjects could have prior systemic therapy, phase two subjects could not","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT02575339","NA","45375953","ENSG00000104313","EFO_0000702","ABSENT NA NA","no biomarker"
"224",224,"ADVANCED HEPATOCELLULAR CANCER","AFP","positive/negative","NA","Protein expression","APATINIB","UNK","II","Advanced, First line","Objective Response Rate(ORR)","NCT03046979","being compared to sorafenib, the current first line","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03046979","DB14765","45139106","ENSG00000081051","EFO_0000311","AFP PROTEIN EXPRESSION POSITIVE/NEGATIVE","pass"
"225",225,"ADVANCED HEPATOCELLULAR CANCER","AFP","positive/negative","NA","Protein expression","PEMBROLIZUMAB","UNK","II","Advanced, Second line","Disease Control Rate (DCR) in Study Participants , Rate of Treatment-Related Adverse Events in Study Participants","NCT02658019","could have been intolerable or refused sorafenib","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT02658019","DB09037","NA","ENSG00000081051","EFO_0000311","AFP PROTEIN EXPRESSION POSITIVE/NEGATIVE","pass"
"226",226,"ADVANCED HEPATOCELLULAR CANCER","absent","NA","NA","NA","OXALIPLATIN","UNK","UNK","Advanced, First line","Objective response rate and/or 1-year survival rate","NCT03166553","couldn’t have any local therapy: like TACE, RFA, surgery","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03166553","DB00526","5310940","ENSG00000104313","EFO_0000311","ABSENT NA NA","no biomarker"
"227",227,"ADVANCED LIVER CANCER","absent","NA","NA","NA","ELEMENE","UNK","UNK","Advanced, Second line","DCR and/or 6-months survival rate","NCT03167775","NA","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03167775","NA","6918391","ENSG00000104313","MONDO_0002691","ABSENT NA NA","no biomarker"
"228",228,"HEPATOCELLULAR CARCINOMA","absent","NA","NA","NA","ANLOTINIB","UNK","II","First&Second line","12-week Progression-free survival rate(PFR 12w)","NCT02809534","one group could not have any prior treatment (systemic) for HCC, another could have failed with sorafenib","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT02809534","DB11885","57380530","ENSG00000104313","EFO_0000182","ABSENT NA NA","no biomarker"
"229",229,"ADVANCED HEPATOCELLULAR CARCINOMA","RB","Positive","NA","Protein expression","LEE011","UNK","II","Advanced, First line","Progression Free Survival","NCT02524119","must be done with TACE","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT02524119","NA","44631912","ENSG00000139687","EFO_0009260","RB PROTEIN EXPRESSION POSITIVE","pass"
"230",230,"ADVANCED HEPATOCELLULAR CANCER","absent","NA","NA","NA","APATINIB MESYLATE TABLETS","VEGFR2","I/II","Advanced, Second line","time to progression","NCT02772029","failed or not compatible with first line","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT02772029","NA","NA","ENSG00000104313","EFO_0000311","ABSENT NA NA","failed drug,no biomarker"
"231",231,"ADVANCED HEPATOCELLULAR CANCER","absent","NA","NA","NA","PEMBROLIZUMAB","UNK","II","Advanced, First&Second line","Objective Response Rate (ORR)","NCT02702414","For Cohort 1: had prior systemic therapy for HCC other than sorafenib, or intercurrent local therapy to the liver tumor between sorafenib and study drug For Cohort 2: had prior systemic therapy in the advanced disease setting","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT02702414","DB09037","NA","ENSG00000104313","EFO_0000311","ABSENT NA NA","no biomarker"
